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Aim and scope of the thesis
The median survival of glioma patient is still very poor and new therapeutic targets have 
to be discovered. The aim of this thesis is to identify genetic alterations in glioma and 
functionally characterize the most promising candidates. We describe several novel me-
thods used to identify these mutations.
In chapter 1 an overview is given of the most common genetic alterations found in the 
different glioma subtypes. In most glioblastomas 3 main pathways are found to be af-
fected. In lower grade gliomas much less was known about common genetic alterations 
until the recent discovery of mutations in the IDH1 gene. In chapter 2 a review is given 
on mutations in the IDH1 and the closely related IDH2 genes in gliomas. It tells us that 
IDH1 is frequently mutated in low grade glioma, in both oligodendroglioma, which often 
have loss of 1p and 19q, and astrocytoma, which are more likely to have P53 mutations. 
Besides that it shows that IDH1 is very specifically mutated in the same spot (R132), but 
that the amino acid change is not always the same; the most common change is R132H, 
but a mix of other changes occurs, we call these non-p.R132H mutations.
The distribution of specific types of IDH1 mutations is listed in chapter 5. We were inte-
rested to find out how these non-p.R132H mutations relate to other main genetic alte-
rations, like P53 mutations and loss of 1p and 19q or  to molecular subgroups in glioma 
on the basis of RNA expression profiles. If so this could suggest functional differences 
between the IDH1 R132H and IDH1 non-p.R132H mutations. A non random distribution 
would also tell us something about the importance of IDH1 mutations in gliomagenesis. 
Chapter 2 shows us that although the mutations found in these genes are very speci-
fic, they (all) cause a loss of normal enzymatic function of the gene. This would make 
us think that IDH1 functions as a tumor suppressor gene. However, tumor measure-
ments of metabolites show that IDH mutated tumors have a higher concentration of 
2-hydroxyglutarate, and enzyme measurements show that mutated IDH1 produces 2-hy-
droxyglutarate, suggesting that mutated IDH1 has oncogenic potential by means of this 
2-hydroxyglutarate. It is still unclear if 2-hydroxyglutarate is the oncogenic effector or a 
simple byproduct. We wanted to know what the effect of the IDH1 R132H mutation was 
on the growth and migration of cell lines, both in vivo and in vitro. Because no glioma 
cell lines harboring the IDH1 R132H mutation were available, we stably over expressed 
IDH1 R132H in several (glioma) cell lines. In chapter 6 a functional analysis of these cell 
lines is given. 
In chapter 4 we describe the functional analysis of the CASPR2 gene. This gene was 
mutated in at least 3 gliomas with decreased expression of the CASPR2 protein in these 
samples. We wanted to know if the CASPR2 gene functioned as a tumor suppressor gene 
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and therefore investigated the effect of expression of the CASPR2 gene on cell prolifera-
tion and migration. 
The technical revolution that first has taken place in the field of RNA and DNA level 
detection and later in high throughput sequencing gave us the opportunity to use exon 
arrays, SNP arrays and next generation sequencing techniques to detect fusion genes 
and to systematically screen for other mutations. Before the array era especially translo-
cations were very hard to screen for and to screen one gene for point mutations or small 
insertions or deletions was a long term project. Exon arrays and SNP arrays provide enor-
mous amounts of data and besides the use of this information for tumor classification or 
the detection of big chromosomal gains and losses, we wanted to integrate this data and 
in this way zoom in on individual genes in a systematic way. In chapter 3 we describe a 
method to detect fusion genes by means of copy number alteration data integrated with 
exon array expression data. We also thought of a way to use exon arrays to screen for 
translocation sites. Chapter 4 describes the detection of a translocation of the CASPR2 
gene detected by means of exon array expression data. 
In chapter 7, we describe the use of next generation sequencing to systematically 
sequence all exons on the 1p and 19q chromosomal arms in oligodendrogliomas. Be-
cause loss of 1p and 19q is common in oligodendrogliomas mutation of a gene on the 
remaining alleles may be a “second hit” on a putative tumor suppressor gene. 
In summary, this thesis describes the search for new genetic alterations in glioma by 
means of novel techniques like exon arrays and next generation sequencing. One can-
didate gene from this screen, the CASPR2 gene, is functionally analyzed, as well as the 
recently discovered R132H mutation in the IDH1 gene.
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Abstract
Gliomas are the most common type of primary brain tumor and have a dismal prognosis. 
Understanding the genetic alterations that drive glioma formation and progression may 
help improve patient prognosis by identification of novel treatment targets. Recently, 
two major studies have performed in-depth mutation analysis of glioblastomas (the 
most common and aggressive subtype of glioma). This systematic approach revealed 
three major pathways that are affected in glioblastomas: The receptor tyrosine kinase 
signaling pathway, the TP53 pathway and the pRB pathway. Apart from frequent mu-
tations in the IDH1/2 gene, much less is known about the causal genetic changes of 
grade II and III (anaplastic) gliomas. Exceptions include TP53 mutations and fusion genes 
involving the BRAF gene in astrocytic and pilocytic glioma subtypes, respectively. In this 
review, we provide an update on all common events involved in the initiation and/or 
progression across the different subtypes of glioma and provide future directions for 
research into the genetic changes. 
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1. Introduction 
Gliomas are the most common primary brain tumor in adults (incidence 5.97 per 
100,000, CBTRUS statistical report 2010, http://www.cbtrus.org/) and can be subdivided 
based on their histological appearance into an astrocytic (A), oligodendroglial (OD), or 
oligoastrocytic (OA) lineage. They can be further subclassified into grades: I (pilocytic 
astrocytomas, PA), II (low grade), III (anaplastic) and IV (glioblastoma, GBM), depending 
on the number of malignant features present (high cellularity, nuclear atypia, mitosis, 
necrosis, and endothelial proliferation). Secondary GBMs are those that have progressed 
from lower grade gliomas, whereas primary GBMs arise de novo. 
The prognosis of glioma patients varies between the different histological subtypes 
and grades; for example, patients with grade II OD have the longest survival (median 
survival 11.5 years) whereas patients with a glioblastoma (the most common subtype 
of glioma) have a median survival of only 4.9 months [1]. Pilocytic astrocytomas are the 
only subtype of glioma with a favorable prognosis (94–96% five year survival) (CBTRUS 
statistical report 2010; [1]). 
Current treatment options involve a combination of surgical resection, radiothe-
rapy and chemotherapy. Complete surgical resection of gliomas is virtually impossible 
due to their invasive growth pattern. Radiotherapy is effective. However, the infiltrating 
cells can only be reached by whole brain irradiation where the benefits of radiotherapy 
may not outweigh the side effects caused by radiation damage. Temozolomide has thus-
far proven effective in improving the median overall survival in glioblastoma by three 
months [2], and is most effective in those in which the MGMT promoter is hyperme-
thylated [3]. Adjuvant procarbazine, CCNU (lomustine) and vincristine (PCV) improved 
progression free survival but not overall survival in anaplastic oligodendrogliomas and 
oligoastrocytomas [4,5]. In these studies, tumors harboring loss of 1p and 19q chromo-
somal arms comprise a favorable subgroup. In spite of these advances, the prognosis 
of gliomas remains poor and therefore other strategies have to be developed. A better 
understanding of the genes (and their associated molecular pathways) involved in glio-
magenesis and/or progression may reveal new options for targeted therapy. 
2. Glioblastoma 
The Cancer Genome Atlas project has published mRNA expression data and DNA copy 
number alteration data of 206 GBMs and has sequenced >600 genes in 91 GBMs [6]. 
The project is still ongoing and ultimately aims to include data from 500 gliomas, but 
already has shown the importance of a systematical approach and high sample numbers. 
Combining all detected homozygous deletions, focal amplifications and validated soma-
tic nucleotide substitutions, they found three major pathways affected in a high percen-
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tage of glioblastomas: receptor tyrosine kinase signaling (altered in 88% of the GBMs), 
TP53 signaling (altered in 87%) and the pRB tumor suppressor pathway (altered in 78%). 
Novel genes in those pathways include the NF1 tumor suppressor gene and PIK3R1. Ano-
ther large study on 22 GBMs sequenced all protein coding genes and performed copy 
number analysis and expression data analysis on these tumors [7]. All genes affected in 
more than two tumors were validated in a set of 80 GBMs. Besides confirmation of affec-
ted oncogenes and tumor suppressor genes in the formerly mentioned three pathways 
(50%, 64% and 68%, respectively) (see Scheme 1 and Table 1), they found the IDH1 gene 
to be mutated in 12% of the GBMs [7]. These mutations occurred in younger patients 
with mostly secondary GBMs and such tumors had a relatively favorable prognosis [7,8]. 
(For a more elaborate discussion on IDH1 see below). 
Scheme 1. The three major pathways affected in a high percentage of glioblastomas and the most 
common genes affected in those pathways. Following the gene names, the percentages of genetic 
alterations found in glioblastoma are depicted. 
Pathways 
RTK 50 88% TP53 64 87% RB 68 78% 
EGFR 
PDGFRA 
ERBB2 
cMET 
PTEN 
PIK3CA 
PIK3R1 
AKT 
FOXO 
RAS 
NF1 
37 45% 
13% 
8% 
4% 
30 36% 
5 10% 
8 10% 
2% 
1% 
2% 
15 18% 
TP53 35 40% RB 11 12% 
CDKN2A-
p14ARF 
49 50% CDK4 14 18% 
MDM2 14% CDK6 1% 
MDM4 7% CCND2 2% 
CDKN2A-
P16INK 
50 52% 
CDKN2B 47% 
CDKN2C 2% 
2.1. Copy Number Alterations 
Copy number amplifications are more frequent in GBMs than in lower grade gliomas 
[9,10]. A distinction can be made between focal, high copy number amplifications (e.g., 
≥7n) and larger, intermediate copy number amplifications (e.g., 3n). High copy ampli-
cons often occur in regions with known oncogenes (EGFR, MDM2 and CDK4), but may 
also occur in other regions [11] (for a summary see [12]). Frequent intermediate copy 
number gains or losses include trisomy of chromosome 7 (42%) and monosomy of chro-
mosome 10 (58%) [6,13,14]. The genes involved in gliomagenesis and/or progression on 
these chromosomes (except for PTEN) remain to be determined. GBMs with trisomy of 
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chromosome 7and loss of chromosome 10 have a poor prognosis [6,13,14]. In general, 
aCGH data can identify three genetic GBM subgroups; one with gain of chromosome 7 
and loss of chromosome 10, one with only chromosome10 loss and one without gain of 
chromosome 7 or loss of chromosome 10 [15]. 
2.2. Receptor Tyrosine Kinase Signaling 
The receptor tyrosine kinase (RTK) signaling pathway is involved in the translation of 
growth factor signals into increased proliferation and survival. The most frequently al-
tered gene in the RTK pathway is EGFR. It is amplified in up to 45% of glioblastomas and 
results in an increase in mRNA and protein expression [6,16,17]. In addition to amplifica-
tion, EGFR is often constitutively activated by variants including EGFRVIII in which exons 
2–7 are deleted [18]. 3’ truncations are also frequently observed [18]. Both variants are 
due to intragenic deletions, are thought to occur following EGFR amplification and result 
in constitutively active proteins [19-22]. Although a number of point mutations are also 
observed in the EGFR gene [6,7], the activating mutations in the ATP binding domain 
observed in lung cancer (NSCLC) are not observed in gliomas [23]. Other RTKs may also 
be affected in GBM and include PDGFRA (amplified in 13%), ERBB2 (mutated in 8%) and 
cMET (amplified in 4%) [6]. 
RTKs signal (a.o.) through phosphoinositide 3 kinases (PI3 kinases) that phosphoryla-
te phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisp-
hosphate (PIP3). This reaction is reversed by PTEN. Of the PI3 kinases, PIK3CA and its 
adaptor protein PIK3R1 are most frequently mutated in GBM (15-27%) [6,7,24,25]. PTEN 
is homozygously deleted in 36% of GBMs and infrequent mutations in downstream PIP3 
targets have been identified in AKT and FOXO (2% AKT amplification, 1% inactivating 
FOXO mutation) [6]. 
Ras is another important protein activated by receptor tyrosine kinases and a key 
regulator of tumorigenesis. Ras mutations (N-Ras, H-Ras, KRas) occur infrequently in 
GBM (2% activating Ras mutations) [6]. However, the NF1 gene, which encodes for the 
Ras inhibiting protein neurofibromin 1 (a RasGAP), is frequently inactivated in GBM (15-
18% inactivating mutations or homozygous deletions) [6,7]. 
2.3. TP53 Signaling 
TP53 signaling is important in apoptosis, cellular senescence and cell cycle arrest in res-
ponse to DNA damage. Most tumor types need to circumvent or shut down the TP53 
pathway. TP53 heterozygous dominant negative point mutations and homozygous de-
letions are common in GBM (35–40%) [6,7]. Two TP53 inhibitors, MDM2 and MDM4, 
that are involved in the ubiquitinylation and degradation of TP53, are amplified in 14% 
and 7% of the glioblastomas, respectively [6]. The CDKN2A locus is also part of the TP53 
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pathway and is frequently deleted or inactivated in glioblastomas (49–50%) [6,7]. One 
of the two genes that can be expressed from the CDKN2A locus is P14ARF, which is an 
inhibitor of MDM2. The CDKN2A locus also encodes for p16INK4A which is part of the 
pRB signaling pathway (see below) 
2.4. RB Signaling 
The retinoblastoma protein (pRB) is a major protein involved in cell cycle progression 
from G1 to S phase. In the hypophosphorylated state pRB binds to the transcription 
factor E2F, thereby preventing cell cycle progression. Phosphorylated pRB does not as-
sociate with E2F, which results in cell cycle progression. The pRB gene is homozygously 
deleted or mutated in 11–12% of the GBMs [6,7]. Interestingly, CDK4, CDK6 and CCND2 
phosphorylate pRB and are amplified in 14–18%, 1% and 2% of glioblastomas, respec-
tively [6,7]. Conversely, CDKN2A/p16INK4A, CDKN2B and CDKN2C, inhibit the different 
CDKs and are frequently inactivated in GBM (homozygously deleted or mutated in 50–
52%, homozygously deleted in 47%, homozygously deleted in 2%, respectively) [6,7]. 
3. Grade II and III Glioma 
In general, only few frequent genetic changes have been identified in lower grade glio-
mas (Table 1). Larger chromosomal aberrations include combined loss of 1p19q in grade 
II and III oligodendroglioma (40–69%) and oligoastrocytoma (44–48%). Such losses are 
far less common in astrocytoma (0–11%) [1,26,27]. The remarkably high frequency of 
LOH of 1p and 19q suggests the remaining arms harbor yet to be identified tumor sup-
pressor genes (Knudson two-hit hypothesis [28]). Frequent mutations have been iden-
tified in IDH1 (all grade II and III gliomas, see below) and TP53 genes (predominantly 
astrocytic). TP53 mutations and LOH of 1p 19q are mutually exclusive [1], thereby distin-
guishing two different pathways of glioma development. Complete hemizygous losses of 
1p are tightly associated with 19q loss and oligodendroglial phenotype and predict lon-
ger overall and progression free survival [29]. However, partial 1p deletions are mainly 
observed in astrocytic tumors, are not associated with 19q loss and have a negative 
prognostic value [29]. 
Based on these genetic changes, three large groups can be genetically characterized 
in low grade and anaplastic gliomas: tumors with TP53 mutations and IDH1/2 mutati-
ons (32%), tumors with LOH 1p19q and IDH1/2 mutations (37%) and tumors with only 
IDH1/2 mutations (17%) [30]. These molecular changes segregate with the distinct his-
tological subgroups of glioma: for example, most of the diffuse astrocytoma have TP53 
and IDH1/2 mutation and most of the oligodendrogliomas have LOH 1p19q and IDH1/2 
mutation. The oligoastrocytomas were more equally distributed among the three dif-
ferent groups (33%, 34% and 19% respectively) [30]. 
Genetic Alterations in Glioma
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IDH1/IDH2 
IDH1 mutations were initially discovered in GBMs by Parsons et al. [7]. However, IDH1 
mutations were detected at much higher frequencies (over 70%) in grade II and II glio-
mas [31-35].; Mutations in the homologous IDH2 gene were also identified (around 5%), 
predominantly in oligodendroglial tumors [32,35]. IDH1 mutations are an early event in 
tumorigenesis [34], are an independent favorable prognostic marker in gliomas and are 
closely associated with1p19q codeletion and MGMT methylation status [36]. IDH1/2 mu-
tations are heterozygous missense mutations affecting highly conserved arginines that 
are involved in substrate binding. Wildtype IDH converts isocitrate into alpha-ketogluta-
rate, whereas mutant IDH enzymes have reduced ability to catalyze this reaction [35]. 
Instead, mutant IDH enzymes have gained the ability to convert alpha-ketoglutarate into 
D-2-hydroxyglutarate [37]. The oncogenic function and the molecular pathway of IDH1/2 
and D-2-hydroxyglutarate are not fully understood yet. However, a recent study suggests 
that IDH1/2 mutations result in an increase in global methylation [38] and IDH1/2 muta-
tions are associated with a more hypermethylated DNA methylation profile [39,40]. It is 
therefore possible that IDH1/2 mutations are involved in oncogenesis by the inactivation 
of tumor suppressor genes following promoter hypermethylation. 
4. Pilocytic Astrocytoma 
The majority of pilocytic astrocytomas are cytogenetically normal [41] except for a small 
tandem dulication of 2 Mb at 7q34 (66%) [42]. This duplication results in a fusion gene 
incorporating the kinase domain of BRAF to KIAA1549 (exon 1-16/15) [42]. This fusion 
gene produces a constitutively active BRAF, which is able to transform NIH3T3 cells [42]. 
Activating BRAF point mutations (V600E/ins 3 bp at 598) can also occur in pilocytic as-
trocytoma [42,43]. 
5. Genetic Alterations in Molecular Subtypes 
Current classification of gliomas is largely based on histological appearance. However, 
histological classification of gliomas is troublesome and subject to interobserver-variati-
on [44-47]. Gliomas may also be classified based on their similarities in gene expression 
profiles [48-50]. Such classification correlates better with survival than histological clas-
sification of gliomas [48]. Distinct genetic changes also segregate into the different mo-
lecular subtypes of glioma [48,50]. For example, EGFR amplifications are predominantly 
found in classical and neural subtypes [50] or in cluster 18 gliomas [48]. IDH1 mutations 
segregate in proneural type GBMs [50] or in gliomas containing + predominantly secon-
dary GBMs (Cluster 22) as well as in gliomas with more favorable prognosis (Clusters 9 
and 17) [48]. 
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6. Epigenetic Changes 
Methylation in cancer often occurs in the promoter regions of tumor suppressor genes 
[51,52]. Inactivation of gene expression by promoter methylation thus contributes to 
tumor formation as the second “hit” in tumor suppressor genes (Knudson’s two-hit hy-
pothesis [28]). Several groups have therefore performed genome wide methylation pro-
filing in GBMs and have identified a subset of tumors that have more favorable prognosis 
[40,53]. These tumors show an overall increase in DNA methylation at CpG sites (CIMP; 
CpG island methylator phenotype) [40]. It remains to be determined whether reversal of 
CIMP status can be used as a treatment for gliomas. 
7. Future Perspectives 
Large scale sequencing efforts, such as those described in this review, have revealed 
an unprecedented insight into the biology of gliomas. The rapid development of novel 
sequencing techniques will lead to even more genetic data in the next decade. It can 
therefore be expected that virtually all genetic changes in all glioma subtypes will be 
identified in the near future. However, not all genetic changes in gliomas (or other tu-
mors) are causal for the disease; mutations can arise during cell division and are then 
found throughout the tumor due to clonal expansion [54]. In fact, the majority of so-
matic mutations in cancer may be such “passenger” mutations [54]. Distinguishing such 
“passenger” mutations from the causal “driver” mutations is therefore required. 
One way to distinguish driver from passenger mutations is by frequency analysis: 
causal genetic changes are thought to occur at a higher incidence than predicted by 
chance. However, few genetic changes are recurrent events (so-called “mountains” in 
the genomic landscape of [55]); only a handful of genes are mutated at frequencies 
>10% not only in gliomas [6,7,54] but also in many other cancer types [56,57]. These stu-
dies show that many more genes are mutated at low frequencies (so-called “hills”). Such 
infrequent candidates have been demonstrated to contribute to tumor formation and/
or progression (see e.g., [58]). Future research will thus require distinguishing “drivers” 
from “passengers” on infrequently mutated genes. 
Eventually, the knowledge of these genetic alterations can be used for the develop-
ment of targeted therapy. However, many infrequent “hills” could indicate that each tu-
mor has its own unique spectrum of causal genetic changes. Treatments aimed at target-
ing these individual genetic changes may therefore be difficult. Nevertheless, it is likely 
that different genetic changes are part of a select set of molecular pathways. Therefore, 
pathway inhibition or reactivation can be used to target a broader range of tumors. In 
the future, it is likely that individual cancer genomes will therefore be sequenced to 
direct targeted therapies. Such practice does require a further increase in sequencing 
capacity and speed and dedicated data analysis pipelines. 
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Table 1. Genes or regions with the most characteristic genetic alterations in glioma subtypes. 
* % are calculated on a mixture of primary and secondary glioblastoma. LOH: loss of heterozygo-
sity; PA: Pilocytic Astrocytoma. 
Tumor Type  Ref. [7]* [6]* [43] [31] [32] [27] [1]* 
PA BRAF 66% 
Oligodendroglioma IDH1/2 69% 74.7–86.7% 
LOH 1p19q 40% 69% 
Oligoastrocytoma IDH1/2 78% 72.3–82.9% 
LOH 1p19q 48% 45% 
TP53 44% 
Astrocytoma IDH1/2 68% 64.9–73.6% 
TP53 53-88% 
Sec Glioblastoma IDH1/2 12% 88% 
TP53 40% 35% 31% 
Prim Glioblastoma EGFR 37% 45% 34% 
CDKN2A 50% 53% 31% 
PTEN 30% 36% 24% 
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Abstract
The discovery of somatic mutations in the gene encoding isocitrate dehydrogenase-1 
(IDH1) in glioblastomas was remarkable because the enzyme was not previously 
identified with any known oncogenic pathway. IDH1 is mutated in up to 75% of grade II 
and grade III diffuse gliomas. Apart from acute myeloid leukaemia, other tumour types 
do not carry IDH1 mutations. Mutations in a homologous gene, IDH2, have also been 
identified, although they are much rarer. Although TP53 mutations and 1p/19q code-
letions are mutually exclusive in gliomas, in both of these genotypes IDH1 mutations 
are common. IDH1 and IDH2 mutations are early events in the development of glio-
mas. Moreover, IDH1 and IDH2 mutations are a major prognostic marker for overall and 
progression-free survival in grade II–IV gliomas. Mutated IDH1has an altered catalytic 
activity that results in the accumulation of 2-hydroxyglutarate. Molecularly, IDH1 and 
IDH2 mutations are heterozygous, affect only a single codon, and rarely occur together. 
Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and 
commonly mutated in gliomas, the altered enzymatic activity of IDH1 may provide a 
fundamentally new understanding of diffuse glioma. 
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Introduction 
In 2008, a genome-wide sequencing study identified mutations in a gene encoding iso-
citrate dehydrogenase (IDH1) in 18 (12%) of 149 samples of glioblastoma multiforme.1 
The mutations were most common in young patients with glioblastomas that had pro-
gressed from low grade gliomas to secondary glioblastoma multiforme. Patients with 
IDH1 mutations were also associated with a longer survival than patients with glioblas-
tomas without IDH1 mutations. Several papers have since identified the IDH1 mutations 
in other glioma subtypes and in various tumour types (table 1). Functional studies2–17 on 
IDH1 found that IDH1 mutations in the gene are highly glioma specific. Investigations 
of large numbers of other tumour types showed that acute myeloid leukaemia (AML) 
was the only cancer other with a high incidence of IDH1 mutations (table 1). IDH1 is the 
most commonly mutated gene in many types of glioma, with incidences of up to 75% in 
grade II and grade III glioma (table 1). IDH1 mutations are always heterozygous missense 
mutations that affect aminoacid residue 132 (figure 1) and are associated with longer 
survival in patients with glioma than patients with glioma without IDH1 mutations (table 
2, figure 2). IDH1 mutations result in a reduced enzymatic activity towards the native 
substrate, isocitrate, and mutant IDH1 catalyses the formation of 2-hydroxyglutarate 
from α-ketoglutarate. 
In addition to IDH1, mutations in a homologous gene, IDH2, with a different sub-
cellular distribution have been identified in gliomas. IDH2 mutation is much less com-
mon than IDH1 mutation; the two rarely occur together, but both seem to be specific 
to gliomas.5,6,11,24 Inactivating mutations in another gene, IDH3B, have been identified in 
patients with retinitis pigmentosa, but they do not seem to be associated with tumour 
formation.25 
Structure and function 
In human beings, five genes encode for isocitrate dehydrogenase: IDH1, IDH2, IDH3A, 
IDH3B, and IDH3G. These genes encode three catalytic isozymes: IDH1, IDH2, and IDH3. 
Both IDH1 and IDH2 function as homodimers whereas IDH3 functions as a heterotetra-
mer composed of two α, one β, and one γ subunit.26 The function of all isocitrate dehy-
drogenases is to catalyse the oxidative decarboxylation of isocitrate into α-ketoglutarate, 
with oxalosuccinate formed as an intermediate product (figure 1).27 In mitochondria this 
reaction is part of the tricarboxicylic-acid cycle (also know as the Krebs cycle). During the 
enzymatic reaction, either nicotinamide adenine dinucleotide (NAD+) in the case of IDH3 
or nicotinamide adenine dinucleotide phosphate (NADP+) for IDH1 and IDH2 function 
as the electron acceptor. Distinct isocitrate dehydrogenase (IDH) isozymes also differ in 
subcellular localisation; IDH1 is located in the cytoplasm and peroxisomes whereas IDH2 
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and IDH3 are found in mitochondria. Neither IDH1 nor IDH2 function as monomers, and 
both require a divalent metal ion, preferably Mn²+, for enzymatic activity.28–34 
Mutation frequency 
Diffuse gliomas are the most common primary brain cancer in adults and typically have 
a poor prognosis.35,36 On the basis of histology, gliomas are classified into astrocytic tu-
mours (75%) and oligodendroglial tumours (25%). Oligodendroglial tumours comprise 
both classic oligodendrogliomas and mixed oligoastrocytic tumours.37 Diffuse gliomas 
are further classified into grade II (or low grade), grade III (anaplastic), and grade IV 
(gliobastoma multiforme) depending on the presence of malignant features. Grade IV 
tumours, are the most common and aggressive type of glioma and are distinguished be-
tween those that occur de novo (primary gliobastoma multiforme) and those that have 
progressed from low grade gliomas (secondary).38 
IDH1 mutation is common in almost all glioma subtypes, ranging from 50% to 80%, 
except in primary gliobastoma multiforme (table 1). IDH1 is among the few genes that 
are commonly mutated in grade II and grade III gliomas.39,40 The prevalence of IDH1 
mutation is much lower in primary (about 5%) than in secondary gliomas than in ana-
plastic gliomas.7,41 IDH2 mutations (about 75%) gliobastoma multiforme. Furthermore, 
are much less common than IDH1 mutations and are IDH1 mutation seems to be more 
common in grade II associated with oligodendrogliomas (table 1).6 IDH1 mutations are 
rarely seen in pilocytic astrocytomas, which are circumscript (non-diffuse) grade I glio-
mas.42 Molecularly, IDH1 mutations are associated with MGMT (O⁶-methylguanine-DNA 
methyltransferase) methylation status, TP53 mutations, and deletions of both 1p and 
19q.3,4,7,22 TP53 mutations and deletions of both 1p and 19q are mutually exclusive and 
are thought to be early events in the development of astrocytomas and oligodendroglio-
mas respectively. 
IDH1 mutations are almost exclusively detected in gliomas. However, of 224 patients 
with AML in one study,14 21 (9%) had IDH1 mutations, which occurred predominantly 
(13 of 80 patients) in otherwise cytogenetically normal cells.14 No other major subtype 
of leukaemia (chronic-lymphoid leukaemia, acute-lymphoid leukaemia, and chronic-my-
eloid leukaemia) was associated with IDH1 mutation (table 1). IDH1 mutations do not 
seem to occur in any of the other tumour types examined, although sporadic mutations 
have been found in paraganglioma, prostate carcinomas, and in a colon cancer metas-
tasis.12,13,43 
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Figure 1: Isocitrate dehydrogenase 1 mutations in gliomas
An example of an MRI of a patient with a glial brain tumour (A). The enzymatic reactions catalysed 
by wild-type and mutant isocitrate dehydrogenase. Isocitrate is converted into α-ketoglutarate by 
wild-type isocitrate dehydrogenase 1 (IDH1). During the reaction, NADP+ is converted into NADPH. 
Mutant IDH1 converts α-ketoglutarate and NADPH into 2-hydroxyglutarate and NADP+(B). Im-
munohistochemistry on formalin-fi xed, paraffi n-embedded-glioma tissue using an antibody spe-
cific for R132H mutated IDH1. At the infi ltrating edge of the tumour into the cortex, only glioma 
cells stain positive18,19 (C). A chromatogram of a tumour wild-type for IDH1 and a tumour that 
harbours a heterozygous mutation (395G→A) on position 395 of IDH1 (D).
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Clinical implications 
Histological diagnosis of gliomas is subject to substantial interobserver variation,44 thus 
IDH1 mutation status can provide an objective marker to identify the glioma subtype. 
IDH1 mutations are rare in primary glioblastoma multiforme and are common in second-
ary glioblastoma multiforme; therefore, IDH1 mutation status can distinguish between 
these two subtypes (sensitivity 71·0–73%, specificity 96%).18 The low incidence of IDH1 
mutation in pilocytic astrocytomas also allows clinically relevant differentiation between 
diffuse and pilocytic astrocytomas (sensitivity 73–83%, specificity 100%).18 Furthermore, 
IDH1 mutations can have a role in distinguishing anaplastic astrocytomas from primary 
glioblastoma multiforme, or astrocytomas from ependymomas.18 Several techniques 
have been developed to detect IDH1 mutations (figure 1).18,19,45,46 These techniques might 
aid diagnosis, even if samples contain little tumour tissue, and allow differentiation be-
tween tumour and reactive gliosis. 
Extensive research has been done to determine the prognostic value of IDH1 
mutations (table 2). Patients with IDH1 mutated glioblastoma multiforme have a bet-
ter prognosis that those without IDH1 mutations,1 with respect to both overall surviv-
al1,5,7,8,10,15,20–23 (figure 2) and progression-free survival.7,20,22 Although patients with an 
IDH1 mutation are generally younger, and that age alone is an independent prognostic 
factor in gliomas, several studies have confirmed by multivariate analyses the indepen-
dent prognostic value of IDH1 mutations.7,10,15,20–22 The major prognostic importance of 
IDH1 mutation status suggests that it should be used as a stratification factor in con-
trolled clinical trials. 
Two studies have examined whether IDH1 mutation status can predict response to 
treatment in gliomas. In a group of patients with dedifferentiated low-grade astrocyto-
mas progressive after radiotherapy response to temozolomide did not differ between 
IDH1 mutant and wild-type tumours.23 In patients with anaplastic oligodendroglial tu-
mours treated with radiotherapy alone or radiotherapy with adjuvant PCV (procarba-
zine, lomustine, and vincristine), the presence of IDH1 mutations had no predictive value 
for outcome to PCV.22 Whether IDH1 mutations have a predictive value in other sub-
groups or treatment regimens needs to be investigated; at present IDH1 mutations seem 
to be mostly prognostic. 
Are IDH1 and IDH2 mutations causal? 
Despite the high mutation frequency, whether IDH1 mutations cause disease is un-
known. Several observations suggest a causal role for IDH1 and IDH2 in tumorigenesis. 
The prevalence and nature of somatically acquired mutations does not suggest a by-
stander mutation.47 Moreover, IDH1 and IDH2 mutations rarely occur together.6 Mutant 
IDH1 causes an accumulation of 2-hydroxyglutarate, high concentrations of which are 
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associated with brain tumours.16,48,49 Specific mutation types segregate into distinct tu-
mour types;6,41 IDH1 mutations are early events in glioma development and have been 
reported to precede both the loss of 1p and 19q and the acquisition of TP53 muta-
tions.3,4 Furthermore, the incidence of IDH1 mutations is higher in grade II than in grade 
III gliomas.7,41 Thus, mutation type and incidence, as well as the timing of the mutation 
suggests a causal role for IDH1 and IDH2 in tumours. 
Table 2: Prognostic value of IDH1 and IDH2 mutations for progression-free survival and overall survival, ac-
cording to tumour type 
n HR (mutant vs 
wildtype) 
HR (mutant vs 
PFS wildtype) 
Median PFS 
OS (months) 
Median OS 
(months)
Grade II–IV gliomas 
Multivariate
7
* 397 0·4 0·3 .. .. 
GBM 
Multivariate
10
† 407 .. .. .. 11·3 vs 27·1 
Multivariate
20
‡ 301 0·4 0·4 6·5 vs 16·2 11·2 vs 30·2 (trend) 
Multivariate
15
§ 159 .. 0·1 .. 8·4 vs 24.0 
Univariate
7 
183 .. .. 8·8 vs 55 14·0 vs 27·4 
Univariate
5 
129§§ .. .. .. 15·0 vs 31.0 
Univariate
1
¶ 105§§ .. .. .. 13·2 vs 45·6 
Grade III gliomas 
Multivariate
21
|| 318 0·4 0·5 .. .. 
Univariate
7
** 121 .. .. 9·2 vs 37·0 19·4 vs 81·1 
Anaplastic astrocytoma 
Univariate
5 
52 .. .. .. 20·0 vs 65·0 
Univariate
8 
21 .. .. .. 22·0 vs 50·0 
Anaplastic oligodendroglioma and anaplastic oligoastrocytoma 
Multivariate
22
†† 159 0·3 0·2 7·8 vs 50·0 16·0 vs not reached 
Grade II gliomas 
Univariate
7
 100 .. .. .. 60·1 vs 150·9 
Progressive low-grade astrocytoma 
Univariate
23
‡‡ 49 .. .. .. 48·0 vs 98·0 
HR=hazard ratio. PFS=progression free survival. OS=overall survival. GBM=glioblastoma multiforme. 
KPS=Karnofsky performance score. *Tumour grade, age, MGMT methylation status, genomic profile (1p and 
19q co-deletion, epidermal growth factor receptor [EGFR] amplification) and treatment were included in the 
multivariate analysis. †Age and gender were included in the multivariate analysis. ‡MGMT methylation status, 
age, KPS, extent of resection, and adjuvant therapy were included. §Molecular cluster, KPS, age, sex, extent 
of surgery, chemotherapy, epidermal growth factor receptor amplification, and 1p and 19q loss were inclu-
ded. ¶This was also significant in TP53 mutated group younger than 35 years. ||Age, KPS, mini-mental status, 
resection, histology, MGMT methylation status, 1p and 19q codeletion, and IDH1 R132H mutation were in-
cluded. **Significant in the non-1p–19q codeleted and non-EGFR amplified group (n=80). ††Necrosis, frontal 
localisation, and 1p and 19q co-deletion were included. ‡‡Age, presenting clinical symptoms, and treatment 
were the same in the two groups. §§Parsons and colleagues
1
 and Yan and colleagues
5
 have a partly overlap-
ping sample set. 
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Mutations of a single codon 
All mutations in IDH1 and IDH2 are somatic, missense, heterozygous, and affect codon 
132 (IDH1) or codon 172 (IDH2). Moreover, both codons have analogous positions in the 
isozymes.50–52 Most mutations are single base transition substitutions: 395G→A for IDH1 
(about 90%), and 515G→A for IDH2 (about 60%). These mutations result in an arginine 
to histidine (R132H) substitution in IDH1 or an arginine to lysine (R172K) substitution in 
IDH2. The remaining IDH1 mutations are, with the exception of R132V (1 of 1630, 0·1%), 
single nucleotide substitutions on neighbouring bases that result in a substitution of 
arginine with cysteine (77 of 1630, 4·7%), glycine (34 of 1630, 2·1%), serine (27 of 1630, 
1·7%), or leucine (13 of 1630, 0·8%).2–10 
Although more than 90% of all mutations in IDH1 are R132H substitutions, several 
studies reported an increased prevalence of other mutation types in specific histological 
subtypes. In gliomas, R132C mutations seem to be much more common in astrocytomas 
(32 of 591, 5·4%) than in oligodendrogliomas (2 of 662, 0·3%).6,41 Additionally, all five 
IDH1-mutated astrocytomas in patients with Li-Fraumeni syndrome (ie, patients with a 
germline TP53 mutation), had R132C substitutions.53 In AML and in sporadic mutations 
of non-gliomas, only 11 of 26 mutations were R132H; R132C comprise most of the re-
maining mutations.12–14,43 Genetic and epigenetic differences might explain differences in 
the incidence of mutation types in various tumour types and subtypes. However, func-
tional differences between R132H and non-R132H mutated IDH1 might also explain the 
segregation of distinct mutation subtypes. 
Because only R132 in IDH1 and R172 in IDH2 are mutated in cancer, they probably 
confer unique properties on the enzyme. Both codons are highly conserved and have 
analogous positions in the isozymes.50–52 In IDH, R132 and R172 are needed for the elec-
trostatic attraction of isocitrate (both α-carboxylates and β-carboxylates)52 and the ac-
tual enzymatic reaction; arginine (ie, R132 and R172) lowers the pK of nearby aspartic 
acids, which accept the cleaved proton of the hydroxyl group (OH–) before transfer to 
NADP+. Under high pH conditions, the enzyme function is conserved by site directed mu-
tagenesis of porcine R133 (corresponding to R172 in human IDH2).52 R132 seems to be 
a structurally important residue when changing between the different conformational 
states of the enzyme. Substitution of histidine for arginine is likely to shift the equilib-
rium to the closed (ligand and NADP+ bound) conformation.16 Therefore, R132 and R172 
are involved in both the substrate binding and the enzymatic reaction. 
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Altered enzymatic activity 
Results of studies examining the functional consequences of IDH1 and IDH2 mutant pro-
teins have shown a strong decrease in the isocitrate-dependent production of reduced 
NADPH production.3,5,17 Such a decrease in enzymatic activity suggests that both IDH1 
and IDH2 are tumour suppressor genes; however, mutant IDH1 has altered substrate 
specificity and is more compatible with an oncogenic function.16 
A tumour suppressor function of wild-type IDH1 is possible because the mutant 
protein exerts a dominant negative effect on its activity. Because IDH1 mutations are 
heterozygous, both wild-type and mutant IDH1 are expressed in a single cell.14 When 
dimers are formed between a mutant and a wild-type protein (heterodimers), mutant 
IDH1 substantially reduces the activity of the wild-type protein.17 Similar findings have 
been reported for IDH2.54 However, many other mutations generated in IDH1 or IDH2, 
which are scattered across the various domains of the IDH1 and IDH2 proteins, also 
strongly reduce enzymatic activity.27,52,55–58 Therefore, if IDH1 and IDH2 do function as 
tumour suppressor genes, then this enzymatic activity is only susceptible to mutation in 
R132 and R172, respectively. 
Two observations contradict a dominant negative effect for IDH1. First, overexpres-
sion of recombinant mutant IDH1 or IDH2 in a cell line with two normal copies of the 
isozymes does not seem to reduce isocitrate dehydrogenase activity.3,5 Zhao and col-
leagues17 showed that the dominant negative effect of mutant IDH1 is dependent on 
the isocitrate concentration,17 but the isocitrate concentration in enzymatic activity 
measurements (using lysates of cells overexpressing recombinant mutant IDH1) were 
too high for such a dominant negative effect to be seen. Additional experiments on cell 
lysates with lower isocitrate concentrations are needed to confirm the dominant nega-
tive effect of mutant IDH1. Second, a dominant negative tumour-suppressor function is 
difficult to reconcile with the reported segregation of R132C mutations in tumour sub-
types;6,14,41 however differences in mutation frequency might be explained by genetic 
and epigenetic differences. Nevertheless, the possibility of a dominant negative function 
of mutant IDH1 or IDH2 in vivo requires further analysis. 
An oncogenic role of IDH1 is most compatible with the reported range of mutations; 
hotspot mutations, with the exception of TP53, are commonly identified in oncogenes 
(eg, H-Ras59, PIK3CA60). This oncogenic role of IDH1 could result from altered substrate 
specificity. Site directed mutagenesis of the Esherichia coli NADP+ dependent isocitrate 
dehydrogenase has shown that point mutations can result in altered specificity for this 
enzyme.61,62 Mutant IDH1 uses α-ketoglutarate as a substrate to produce 2-hydroxyglu-
tarate (figure 1).16 Concentrations of 2-hydroxylglutarate increase to over 50 times that 
of normal concentrations in IDH1 mutated tumours.16 Mutated IDH1 generates the (R)-
enantiomer of 2-hydroxyglutarate (R-2HG). Accumulation of R-2HG is associated with 
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D-2-hydroxyglutaric aciduria, a rare neurometabolic disorder with highly variable phe-
notypes, caused by a defect in D-2-hydroxyglutarate dehydrogenase. The S-enantiomer 
of 2-hydroxyglutarate (S-2HG) is dehydrated to α-ketoglutarate by the metabolic repair 
enzyme L-2-hydroxyglutarate dehydrogenase.63 L-2 hydroxyglutaric aciduria, a hereditary 
encephalopathy due to a defect in L-2-hydroxyglutarate dehydrogenase, is associated 
with different brain tumour types, some of which are not associated with IDH1 muta-
tions (ependymomas and medulloblastomas).48,49 S-2HG is not a known intermediate 
in any mammalian pathway.63 Moreover, S-2HG and R-2HG exert different biological 
effects.64 Unlike L-2-hydroxyglutaric aciduria, D-2 hydroxyglutaric aciduria is not associ-
ated with tumour formation. Thus, how an increase in R-2HG contributes to tumour 
formation needs to be investigated. 
Cellular functions affected by mutant IDH1 and IDH2 
Although IDH1 mediates a reaction identical to that which happens in the tricarboxylic-
acid cycle, IDH1 does not play a direct part in the reaction because it is localised in the 
cytosol. Thus, IDH1 does not seem to mediate the Warburg effect (the observation that 
Figure 2: The prognostic value of isocitrate dehydrogenase 1 mutation status 
Overall survival in 159 patients (univariate analysis) from a prospective randomised phase 3 stu-
dy22 on procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglioma 
(EORTC study 26951), in whom isocitrate dehydrogenase mutations could be determined.22 Ob-
served events 70 in IDH1 not mutated, 26 events in IDH1 mutated. 
O
ve
ra
ll 
su
rv
iv
al
100
80
60
40
20
0
0 4321 6
Years
90
70
50
30
10
75 8
Number at risk
IDH1 not mutated 86 55 32 22 12 8 5 1 
IDH1 mutated 73 70 59 48 34 18 8 5  
IDH1 not mutated
IDH1 mutated
p<0·0001
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even under normoxic conditions tumour cells preferentially use glycolysis over aerobic 
respiration).65 Other tumour-associated mutations in metabolic enzymes have been de-
scribed in hereditary phaeochromocytoma-paraganglioma syndrome, hereditary leio-
Figure 3: Pathways affected by products of isocitrate dehydrogenase 1 
Products of isocitrate dehydrogenase 1 (IDH1) are used in various processes. NADPH is used as a 
cofactor in palmitate synthesis (A), fatty-acid chain elongation (B), and antioxidant formation (C). 
NADPH is also used as a cofactor in the rate limiting step ofcholesterol synthesis by the enzyme 
3-hydroxy-3-methylglutaryl-coenzyme A reductase (D). Hypoxia-inducible factor 1α (HIF1α) de-
gradation; under normoxic conditions HIF1α is hydroxylated by egl nine homologue 3 (EGLN3), 
in a reaction that requires α-ketoglutarate as a substrate. This reaction results in the generation 
of succinate and hydroxylated HIF1α, which allow the von Hippel-Lindau (VHL) tumour suppres-
sor to bind HIF1α, resulting in the proteasomal degradation of HIF1α. The reaction catalysed by 
EGLN is inhibited by succinate and fumarate. Under hypoxic conditions the hydroxylation does not 
occur and allows HIF1α to form a complex with HIF1β. This complex binds to hypoxia-responsive 
elements (HRE) in the DNA to promote transcription of HIF responsive genes such as those en-
coding vascular endothelial growth factor (VEGF), p21, and insulin-like growth factor 2 (E; IGF2). 
ACP=acyl-carrier protein. Ub=ubiquitin. 
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myomatosis, and renal-cell cancer. Hereditary phaeochromocytoma-paragangliomas 
have dysfunctional succinate-dehydrogenase complexes, and hereditary leiomyomatosis 
and renal-cell cancer have dysfunctional fumarate hydratase.65,66 Because IDH1 is not 
part of the tricarboxylic-acid cycle, the IDH1 mutations in gliomas are different from the 
inactivating mutations in the metabolic pathways of other tumour types. 
Little is known about cytosolic IDH1 and its cellular function in tumours. Homozy-
gous deletions are embryonically lethal in Drosophila melanogaster.67 The biochemical 
role of IDH1 in α-ketoglutarate and NADPH production allow the cellular function of 
IDH1 to be inferred. Biochemical pathways might be affected by and fatty-acid biosyn-
thetic pathways (figure 3).68,69 In changes in cellular α-ketoglutarate and NADPH nucleic-
acid synthesis, IDH1 competes with the pentose concentrations. The anabolic pathways 
of lipid synthesis, phosphate pathway for NADP+ as an electron acceptor.70 cholesterol 
synthesis, and fatty–acid-chain elongation Cytosolic IDH attenuates the glucose-induced 
increase depend on cytoplasmic NADPH. IDH1 knock-in mice in pyruvate cycling in 
the tricarboxylic-acid cycle, show substantial changes in lipid metabolism perhaps by 
affecting the concentrations of organic acid,71 (eg, hyperlipidaemia, fatty liver, and obe-
sity). and is involved in glucose-stimulated insulin secretion Furthermore, IDH1 activity is 
regulated by cholesterol in pancreatic islet cells.71 α-Ketoglutarate might affect 
the activity of IDH isozymes by end product inhibition.72 Finally, 2-hydroxyglutarate 
metabolism might be affected as mutant IDH1 converts α-ketoglutarate to 2-hydroxy-
glutarate.16 
Several biochemical pathways might be affected by changes in α-ketoglutarate and 
NADPH concentrations (figure 3). Overexpression of IDH1 results in increased protection 
against reactive-oxygen species as well as protection against radiation, whereas inhibi-
tion of IDH1 results in increased sensitivity.73–77 Similarly, overexpression of IDH2 result 
in a decrease of intracellular reactive oxygen species.75 Although cellular response to oxi-
dative stress might be altered in tumours with mutated IDH, this is not reflected in an 
increase in the number of mutations.1,47,77 IDH1 expression also changes in response to 
other kinds of stressors, such as protein excretion by Helicobacter pylori and heat.78,79 
IDH mutations might also play a part in the cellular migration and cellular response to 
hypoxia. For example, inhibition of cytosolic IDH1 has been reported to increase lactate 
production, which promotes migration of glioma cells.71,80 
α-ketoglutarate promotes the degradation of hypoxia inducible factor (HIF) 1 α, 
through EGLN (egl nine homologue) prolyl hydroxylases (figure 3). Activation of the 
HIF pathway results in the induction of vasucular endothelial growth factor (VEGF).81 
However, the most vascularised gliomas (primary glioblastoma multiforme) have the 
lowest incidence of IDH1 mutation among glioma. This finding suggests that decreased 
α-ketoglutarate concentrations might affect other HIF dependent (energy metabolism) 
or independent pathways (EGLN-related apoptosis).17,65,81–83 Nonetheless, the HIF path-
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way is likely to be affected in tumours with mutations in metabolic enzymes, such as in 
phaeochromocytoma paraganglioma syndrome.84 By contrast with glioma, IDH1 mutat-
ed AML does not show an increased expression of HIF1α downstream target genes.14,17 
Moreover, other biochemical and cellular pathways are affected by mutations in IDH1 
and IDH2, and the alternative products generated by mutated IDH1 or IDH2 might affect 
entirely different pathways. Further investigation is needed to establish whether IDH1 
and IDH2 are functionally important to tumour formation and tumour progression. 
Conclusion 
The incidence of IDH1 mutation is very high in most diffuse gliomas, but not in primary 
glioblastomas, and to a lesser extent in AML. Mutations in the homologous IDH2 gene 
also occur albeit with a much lower incidence than IDH1. These mutations are early 
events in gliomagenesis, and arise both in TP53 mutated astrocytomas and in 1p and 
19q codeleted oligodendrogliomas. IDH1 is a strong prognostic marker for overall sur-
vival and progression-free survival in gliomas, suggesting that future clinical trials might 
need stratification by IDH1 mutation status. Molecularly, IDH1 and IDH2 mutations are 
inversely correlated, heterozygous, affect a single codon, and result in different catalytic 
properties. Because of the high mutation frequency, mutated IDH1 could potentially 
form a good target for new treatments. IDH1 is expressed at high levels and seems to 
be expressed in all tumour cells. The three-dimensional structure of the native protein 
has also been identified. However, for effective pharmacological intervention, research 
into tumour-cell biology and biochemical defects associated with IDH1 and IDH2 muta-
tions is needed. Further clinical research will identify the diagnostic relevance of these 
mutations. 
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Abstract
We performed genotyping and exon-level expression profiling on 21 glioblastomas 
(GBMs) and 19 oligodendrogliomas (ODs) to identify genes involved in glioma initiation 
and/or progression. Low-copy number amplifications (2.5 < n < 7) and high-copy number 
amplifications (n > 7) were more frequently observed in GBMs; ODs generally have more 
hetero zygous deletions per tumor. Four high-copy amplicons were identified in more 
than one sample and resulted in overex pression of the known oncogenes EGFR, MDM2, 
and CDK4. In the fourth amplicon, RBBP5, a member of the RB pathway, may act as a 
novel oncogene in GBMs. Not all hCNAs contain known genes, which may suggest that 
other transcriptional and/or regulatory elements are the target for amplification. Regi-
ons with most frequent allelic loss, both in ODs and GBMs, resulted in a reduced expres-
sion of known tumor suppressor genes. We identified a homozygous deletion spanning 
the Pragmin gene in one sample, but direct sequencing of all coding exons in 20 other 
glioma samples failed to detect addi tional genetic changes. Finally, we screened for fu-
sion genes by identifying aberrant 5'-3'
 
expression of genes that lie over regions of a copy 
number change. A fusion gene between exon 11 of LEO1 and exon 10 of SLC12A1 was 
identified. Our data show that integrated genomic profiling can identify genes involved 
in tumor initiation, and/or progression and can be used as an approach to identify novel 
fusion genes. 
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Introduction 
In the Western world, more than 40,000 people are diagnosed with a malignant pri-
mary brain tu mor each year (CBTRUS 2004-2005 statistical report; www.cbtrus.org). Dif-
fuse gliomas are the most common histological subtype in adults with an often dismal 
prognosis and invariably fatal out come. Based on their histological appearance, gliomas 
can be divided into astrocytic tumors (75%), pure oligodendroglial tumors, and mixed 
oligoastrocytic tumors (25%) according to stand ard WHO classification (Kleihues and 
Cavenee, 2000). Glioblastomas (GBM) is the most malig nant and most common of the 
astrocytic tumors and can be divided into those that have devel oped from lower grade 
gliomas (secondary or pro gressive GBM) and those that have formed de novo (primary 
or de novo GBM). Despite advan ces in neurosurgery, chemotherapy and radiother apy, 
the prognosis for most glioma patients remains dismal. For example, the median survival 
for GBM is 9–12 months (Ohgaki and Kleihues, 2005). This dismal prognosis is reflected 
in the disproportionally high-mortality rate of gliomas compared to most other types of 
cancer. The treatment of these tumors therefore urgently requires improvement. 
Genetic changes involved in glioma-genesis or progression are potential therapeutic 
targets, and a number of such changes have been identified in gliomas. In GBMs, causal 
genes include the EGFR, MDM2, CDK4, and MDM4 oncogenes and the PTEN and CD-
KN2A tumor suppressor genes (Louis, 2006; Cancer Genome Atlas Research 2008; Pars-
ons et al., 2008). In lower grade oligo dendrogliomas (ODs), very few genes have thus far 
been identified with the notable exception of the frequently mutated IDH1 gene (Balss 
et al., 2008; Parsons et al., 2008; Bleeker et al., 2009; Watanabe et al., 2009; Yan et al., 
2009). Causal genetic changes therefore remain to be identified in the various histologi-
cal subtypes of glioma. 
Recent data on glial brain tumors have indi cated that integrated genomic profiling 
(overlay ing copy number aberrations [CNAs] onto gene expression profiles) can further 
narrow down on candidate causal genes (Bredel et al., 2005; Nigro et al., 2005; Liu et 
al., 2006; Ruano et al., 2006; Beroukhim et al., 2007; Lo et al., 2007; de Tayrac et al., 
2009). However, integrated genomic profil ing has mainly focused on GBMs and not on 
other histological subtypes. We therefore per formed integrated genomic profiling both 
on GBMs and ODs using high-density SNP arrays and exon-level expression profiles. 
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Materials and methods 
Tumor Samples 
All glioma samples were derived from patients treated within the Erasmus MC. Patient 
data and histological diagnosis are listed in Supporting In-formation Table I. Samples 
were collected imme diately after surgical resection, snap frozen, and stored at -80°C as 
described (French et al., 2005, 2007). All samples were visually inspected on 5-lm H&E-
stained frozen sections by the neuro pathologist (J.M.K.) and revealed at least 70% tu mor 
nuclei for each specimen. Tissue adjacent to the inspected sections was subsequently 
used for nucleic acid isolation. Forty glioma samples of the following histologies were 
selected for this study: 17 anaplastic oligodendrogliomas (ODIIIs), 2 low-grade oligoden-
drogliomas (ODIIs), and 21 GBMs. Four control brain samples from patients with no his-
tory of neurological disease were also included (ctrs). 
Nucleic Acid Isolation, cDNA Synthesis, and Array Hybridization 
High-quality genomic DNA was isolated from 20 to 40 cryostat sections of 40-lm thick-
ness using the QIAmp DNA mini kit (Qiagen) accord ing to the manufacturer’s instruction. 
Sample labeling and array hybridization on 250k NspI arrays was performed using high-
quality genomic DNA according to the Genechip Mapping 500k Assay Manual. A com-
bination of four nondiseased brain samples run in addition to the tumor sam ples and 
six publicly available reference samples (www.affymetrix.com) were used as genotyping 
reference. Average SNP call rate was 93.6% (range, 87.9-97.4). 
Total RNA was isolated from 20 to 40 (40-lm) cryostat sections adjacent to those 
used for copy number analysis using Trizol (Invitrogen, Breda, The Netherlands) accor-
ding to the manufac turer’s instructions. Exon-level expression profiles have been repor-
ted previously (French et al., 2007; Schutte et al., 2008). 
Data Integration 
Cel files from genotyping arrays were imported into Partek Genomics Suite 6.08 (Partek, 
St. Louis, Missouri). Baseline allele intensities were defined using all control samples. 
Regions with copy number variations (CNVs) were identified and exported to Excel. Ge-
nomic positions of genes were then overlayed onto regions of CNV. Genes were defined 
as being in a region of CNV when the regional CNV average was <0.80 for a homozygous 
deletion (homDel), between 0.8 and 1.65 for a heterozygous deletion (hetDel), between 
2.5 and 7 for low-copy number amplifi cation (lCNA), and >7 for high-copy amplifica-
tion (hCNA). The lower limit of amplification detection (2.5) was chosen to allow for 
the pres ence of non-neoplastic tissue and to detect focal copy number gains. As can 
be expected, increas ing the lower limit of detection from 2.5 to 2.7 or 2.9 will decrease 
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the number of detected regions (81% and 67%, respectively). However, the regions that 
have copy number changes between 2.5 and 2.9 are identified across the genome and 
not restricted to defined ‘‘hotspots.’’ Therefore, increasing the lower limit of detection 
would not affect the results (data not shown). 
The ratio of 7.0 to distinguish between low and high-copy number gain is based on 
Supporti ng Information Figure 2. This figure shows that large amplicons (>6 Mb) never 
exceed copy number gains of seven. Changing the cutoff value between hCNA and lCNA 
from 7.0 to 6.0 would result in the identification of seven additional hCNAs. However, 
all seven regions are unique and show no overlap with hCNAs of other tumors (data not 
shown) 
The chromosomal location of genes on HuEx_1.0_st arrays was then used to deter-
mine whether a gene resided in a region of CNV. If more than one tumor showed CNV at 
the same locus/gene, the average expression level was taken. We also identified all ge-
nes that only partly overlapped the region with CNV. These genes were used to identify 
fusion genes as is outlined in the Results and Discussion section. Copy number changes 
were visualized using CNAG 3.0 software (Nannya et al., 2005; Yama moto et al., 2007). 
All statistical analysis was per formed using t tests, unless indicated otherwise. 
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5'
 
Rapid amplification of cDNA ends (RACE) polymerized chain reaction (PCR) was per-
formed on cDNA of sample 96 using the Marathon RACE kit (Clontech, Palo Alto, CA) 
according to the manufacturer’s protocol (French et al., 2001). Primers used for 5'
 
RACE 
and RT-PCR confir mation were designed using primer 3 (frodo.wi. mit.edu) and stated in 
Supporting Information Table II. 
Results and discussion 
CNAs in ODs and GBMs 
We first screened for differences between ODs (grades II [n = 2] and III [n = 17]) and 
GBMs (n = 21) in copy number aberration (CNA) ampli tude and frequency. In general, 
homozygous deletions were significantly smaller than hetero zygous deletions (P < 0.001) 
as were hCNAs compared to lCNAs (P < 0.001, see also Supporti ng Information Figs. 1 
and 2). It is possible that the smaller size of hCNAs are a result of struc tural (high-copy 
ampifications require more energy to maintain and therefore are selected against) and/
or functional (to avoid coamplifica tion of genes that have growth inhibitory effects) size 
constraints. lCNAs may also be larger, because more tumor-promoting genes reside on 
the region. 
All tumors showed CNAs, although the distri bution between different types of CNAs 
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varies between histological subtypes. For example, both lCNAs and hCNAs were more 
frequently observed in GBMs than ODs; 21 of 21 versus 15 of 19 for lCNAs P < 0.05 and 
16 of 21 versus 1 of 19 for hCNAs, P < 0.001, Fisher’s exact test. Homozygous and hetero-
zygous deletions were observed at roughly equal frequency in GBMs and ODs; homDels 
were observed in 7 of 21 GBMs and 4 of 19 ODs, hetDels in 20 of 21 GBMs and 19 of 19 
ODs. 
Apart from the number of ODs and GBMs that exhibit copy number changes, the 
average num ber of CNAs per tumor also differs between the histological subtypes (Sup-
porting Information Fig. 3). For example, lCNAs and hCNAs were more prevalent in GBMs 
(7.0 ± 8.2 vs. 2.7 ± 3.2 P < 0.05 and 2.4 ± 3.1 vs. 0.2 ± 0.9, P < 0.01, respectively), and het-
Dels were more prevalent in ODs (3.3 ± 4.2 vs. 5.8 ± 3.1 P < 0.05). Our data thus indicate 
that histological subtypes differ in CNA type (more GBMs have copy number gains than 
ODs) as well as copy number fre quency (copy number gains are more frequent in GBMs 
than ODs, whereas hetDels are more fre quent in ODs). 
CNA Amplitude, Frequency, and Gene Expression 
All regions of CNA were overlaid onto the chromosomal location of genes present on the 
HuEx_1.0_st arrays. This gene-centric overlay allows direct comparison with the genes’ 
expres sion level (see below). Fold changes in copy number gains for each histological 
subtype is shown in Figure 1A. Many regions show lCNAs, whereas four distinct regions 
with hCNAs were identified [residing on chromosomes 1, 7, and 12 (2x)]. The frequency 
of copy number gains is shown in Figures 1B and 1C for hCNAs and lCNAs, respectively. 
The frequency of deletions is shown in Figure 1D. Regions frequently ampli fied include 
chromosomes 1 and 7 in GBM and 7q in ODs. Regions with genomic loss observed in-
clude chromosomes/chromosome arms 9p, 10, 13, and 14 in GBMs and 1p, 4, 9p, and 
19q in ODs. We then examined whether genes that re side on regions of chromosomal 
gain have a diff erent expression level in amplified versus nonamplified samples. In ge-
neral, hCNAs are associated with a markedly higher expression level in amplified ver-
sus nonamplified samples (Fig. 1E, Table I), whereas genes that reside in lCNA regions 
show more modest differential expression (Fig. 1F). Known oncogenes EGFR, CDK4, and 
MDM2 all show a greater than sixfold increase in gene expression level. Approximately 
one-third of all genes that reside in regions of lCNA show an increase in gene expression 
level >20% (both in GBMs and in ODs). Similarly, in regions of deletion, approximately 
one-third of all genes show a reduction in expression level >20%. Known tumor suppres-
sor genes PTEN and CDKN2A show a >50% reduction in expression levels (GEO accession 
number GSE 9385, ana lyzed data available on request). 
It should be noted that not all regions of CNA harbor genes. In 32 regions with CNA 
(16 ampli fications and 16 deletions), genes were absent on the HuEx_1.0_st arrays. Ten 
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of these regions are in high-copy number amplicons. In four of these hCNA regions, 
we observed clear overexpression of several probesets that lie outside the anno tated 
genes (‘‘full’’ probesets, Supporting infor mation Fig. 4). This suggests that copy number-
dependent, transcriptionally active regions reside on at least a subset of these CNAs, and 
it is pos sible that such regions contribute to tumor formation. 
Figure 1. Integrated genomic profiling in GBMs and ODs. A: Fold changes in copy number gains in 
GBMs (red) and ODs (blue). Four distinct regions of high-copy number amplifications are identified 
on chromosomes 1, 7, and 12 (23), whereas many regions show low copy number gains. The fre-
quency of high-copy number gains (B), low-copy number gains (C), and deletions (D) plotted at 
each chro mosomal position. Regions frequently amplified in GBMs include chromosomes/chro-
mosomal arms 1, and 7 in GBM and 7q in ODs. 
BRALTEN ET AL.
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Regions with genomic loss observed include chromosomes/chromo somal 9p, 10, 
13, and 14 in GBMs and 1p, 19q, 4, and 9p in ODs. E: Genes that reside on regions of 
hCNA show markedly higher expres sion levels in amplified versus nonamplified samples 
whereas genes that reside on regions of lCNA (F) show more modest differential expres-
sion levels. Not all chromosomes are labeled on the X axis due to space constraints. 
[Color figure can be viewed in the online issue, which is available at www.interscience.
wiley.com.] 
Integrated Genomic Profiling Identifies RBBP5 as a Candidate Oncogene in GBM 
We next screened for candidate oncogenes based on our genomic and transcriptomic 
data. Genes that are involved in gliomagenesis and/or tumor progression often reside 
on frequently amplified hCNAs and show strong mRNA over expression. Examples in-
clude the EGFR, CDK4, and MDM2 oncogenes (Bredel et al., 2005; Nigro et al., 2005; 
Louis, 2006; Ruano et al., 2006; Can cer Genome Atlas Research, 2008; Parsons et al., 
2008). We therefore identified all genes that re side on recurrent hCNAs. Most of the 
genes on these amplicons indeed show strong overexpres sion (Table I). The candidates 
include the onco genes EGFR, CDK4, and MDM2. However, the amplicon in chromosome 
band 1q32 does not contain any of the known glioma oncogenes. It has been suggested 
that the MDM4 gene is the main amplification target in this amplicon (Rie menschneider 
et al., 2003) although it is not always coamplified in gliomas with hCNA of 1q32 [this 
Table 1. Genes on Frequent hCNAs Often Show a Strong Increase in Expression
INTEGRATED GENOMIC PROFILING IN GLIOMAS
Chr 1 n Fc Chr 12 n Fc Chr 12 n Fc Chr 7 n Fc 
LRRN2 
NFASC 
CNTN2 
TMEM81 
RBBP5 
RIPK5 
3  
3  
3  
3  
3  
3 
4.9 
5.2 
1.7 
4.9 
8.9 
2.4 
GLI1  
ARHGAP9  
MARS  
CENTG1  
TSPAN31  
CDK4  
Mar-09  
CYP27B1  
METTL1  
FAM119B  
TSFM  
AVIL  
XRCC6BP1 
3  
3  
3  
4  
4  
4  
4  
4  
4  
4  
4  
4  
3 
6.2 
1.4 
9.8 
4.2 
9.8 
11.4 
15.7 
9.0 
21.3 
15.0 
9.6 
9.2 
20.4 
MDM2  
CPM  
FRS2  
CCT2  
LRRC10  
BEST3  
RAB3IP 
4  
4  
3  
3  
3  
3  
3 
12.1 
10.5 
5.1 
8.4 
1.5 
2.8 
1.2 
VSTM2A  
SEC61G  
EGFR  
LANCL2  
ECOP 
10  
11  
15  
8  
7 
2.6 
14.7 
6.9 
5.9 
2.4 
Fc, fold change amplified versus nonamplified; n, number of samples showing hCNA. 
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study and see, e.g., (Rickman et al., 2001)]. Because single amplicons may contain sev-
eral causal genes (Holtkamp et al., 2007) and the observation that MDM4 is not always 
coampli fied, the 1q32 amplicon may contain additional oncogenes. 
RBBP5 is one of the genes that reside on the 1q32 amplicon and shows strong dif-
ferential expression. RBBP5 was identified as an RB-bind ing protein (Saijo et al., 1995) 
and members of the RB pathway are required for G1 ! S-phase transi tion (Sherr, 1993; 
Medema et al., 1995; Yamanaka et al., 2008). Our data indicate that RBBP5 ampli fication 
(3 of 21) appears to be mutually exclusive from CDK4 amplification (4 of 21), another 
mem ber of the RB pathway. Similarly, in both the Rembrandt (Madhavan et al., 2009) 
and Cancer genome (Cancer Genome Atlas Research, 2008; Freire et al., 2008) datasets, 
overexpression of RBBP5 (3 of 139 and 5 of 236, respectively) does not occur in samples 
with CDK4 overexpression (21 of 129 and 32 of 236). These data may indicate that RBBP5 
is a novel oncogene in GBM although the frequency of amplification is too low to reach 
statistical significance. 
Candidate Tumor Suppressor Genes 
Tumor suppressor genes commonly reside in regions with (bi-) allelic loss within the mi-
nimal region of overlap. As a result, these genes show a reduction in expression levels. 
We therefore screened for tumor suppressor genes in our data set by screening for regi-
ons of homozygous chro mosomal loss. Genes within these regions include established 
tumor suppressor genes CDKN2A and PTEN. Few other regions with homozygous deleti-
ons were observed. However, in GBM142, a small homozygous deletion was identified 
that spans the entire Pragmin gene (Fig. 2A). No other genes were present in this region. 
As a result, the gene is expressed at lower levels on HuEx_1.0_st arrays (more than two-
fold reduction, Fig. 2B) and on HU133 plus 2.0 arrays [more than fourfold reduction 
(Gravendeel et al., 2009)]. 
We were unable to determine whether the Pragmin deletion is somatic as no con-
trol DNA was available for this patient. It is therefore possi ble that the genomic deletion 
represents a rare structural variant. However, such variants have not been identified in 
other control samples (see projects.tcag.ca/variation). Thus far, only one intraintronic 
deletion that is unlikely to disrupt the Pragmin open reading frame has been identi fied. 
Based on the reduced expression and single homozygous deletion, we subjected Prag-
min to further mutational analysis. 
We screened for genetic changes in the Prag min gene by direct sequencing of all 
coding exons in an additional 10 GBMs and 10 ODs. No mutations were found in any of 
the coding exons. In addition, we screened for genomic changes in the Pragmin gene in a 
large external dataset (Can cer Genome Atlas Research, 2008; Freire et al., 2008). In this 
dataset, no tumors were identified with genomic changes in the Pragmin gene (data not 
shown). We also screened for aberrant 
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Figure 2. Identification of Pragmin 
as a candidate tumor suppres sor 
gene. A: In GBM142, a homozygous 
deletion was identified on 8p23.1 
(genomic position 8.2–8.3 Mb) that 
spanned the entire Prag min gene. 
No other gene resides in the deleted 
region. B: Pragmin expression is 
markedly reduced following deletion 
in GBM142. Values are ±SD. [Color 
figure can be viewed in the online 
issue, which is available at www.in-
terscience.wiley.com.] 
Pragmin expression in three large external data sets: GSE16011 (Gravendeel et al., 2009), 
GSE7696 (Murat et al., 2008), and the Rem brandt dataset (caintegrator.nci.nih.gov/Rem-
brandt). Only three samples showed a more than fourfold-reduced Pragmin expression: 
Samples GBM142 (the identical sample as used for this study) and GBM432 in GSE16011 
and E08021 in the Rembrandt dataset (Supporting Information Fig. 5). Whether the reduced 
Pragmin expression in these samples is due to a genomic change remains to be determined. 
Pragmin has thus far not been implicated in glioma initiation and/or progression. 
Functionally, Pragmin affects actin cytoskeletal rearrangement and cell contraction 
through RhoA activation (Tanaka et al., 2006). The cytoskeletal rearrange ments render 
it is possible that Pragmin plays a role in the motility of gliomas cells. However, the low 
frequency of Pragmin mutations suggests that this gene is not often involved in glioma 
initia tion and/or progression. 
Integrated Genomic Analysis Identifies Translocations 
A genomic breakpoint occurs at each site of a copy number change. Such breakpoints are 
a potential source of fusion genes when the coding region of one gene is inserted into 
the transcribed region of a different gene. We therefore hypothe sized that screening 
for genes that reside over chromosomal breakpoints may identify fusion genes. In our 
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dataset, 244 genes reside over changes in copy number (26, 82, and 136 for hCNA, lCNA, 
and deletions, respectively). We then focused our analysis on those genes of which the 
5'
 
end resides in a deleted region; high expression of the 3'-end would suggest that the 
3'
 
end is driven either by a promoter within the same gene (alternative promoter) or by 
a pro moter from a different gene (fusion gene). 
Forty-three candidates have a deletion of the 5'
 
end of the gene. We then visually 
inspected all candidates for differential expression between the 3'
 
and 5'
 
ends of the 
transcript. In one of the can didates (SLC12A1/BSC1/NKCC2), a high-3'
 
expression was ob-
served, whereas the 5'
 
end was not expressed. The region in which 3'
 
expression occurs 
matches the change in copy number on SNP arrays (Figs. 3A and 3B). 5'
 
RACE-PCR was 
performed using primers located in the expressed region and identified that LEO1 was 
fused at the 5'
 
end of the SLC12A1 gene (Fig. 3C). The breakpoints occurred at intron–
exon boundaries and resulted in an in-frame fusion between exon 11 of LEO1 and exon 
10 of SLC12A1. The fusion gene was confirmed by three independent RT PCR reactions 
Figure 3. Identification of a LEO1-SLC12A1 fusion gene. A: In GBM96 on chromosome 15q21.1 
(genomic location 46.3 Mb), the 5'
 
end of SLC12A1 was identified to lie in a region of chromo-
somal loss whereas the 3'
 
end does not. The arrow denotes the location of SLC12A1.B: SLC12A1 
in GBM96 shows high-3'
 
expression, whereas the 5'
 
end is not expressed. The region in which 3'
 
expression occurs matches the change in copy number on SNP arrays. SLC12A1 is not expressed 
in any of the other samples; values are ±SD. C: 5
0 
RACE PCR identified an in-frame fusion gene 
between exon 11 of LEO1 and exon 10 of SLC12A1. D: The LEO1-SLC12A1 fusion gene is confirmed 
by an independent RT-PCR reaction. None of the other tumor samples investigated showed a si-
milar translocation (data not shown). [Color figure can be viewed in the online issue, which is 
available at www.interscience.wiley.com.] 
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(Fig. 3D and data not shown). In our dataset, no other tumor appeared to have a similar 
translocation (data not shown). 
To determine whether the LEO1/SLC12A1 fusion is a recurrent genetic aberration in 
gliomas, we screened for genomic changes in a large exter nal dataset (Cancer Genome 
Atlas Research, 2008; Freire et al., 2008). No tumors were detected that have chromo-
somal aberrations in SLC12A1 and/or LEO1 in this dataset (data not shown). In addi-
tion, as SLC12A1 expression is re stricted to adult kidney (Supporting Information Fig. 
6), we screened for aberrantly high-SLC12A1 expression in four large external datasets: 
GSE16011 (Gravendeel et al., 2009), GSE7696 (Murat et al., 2008), and the Rembrandt 
and TCGA datasets (Supporting Information Fig. 5). Of the 869 glioma samples analyzed, 
two samples show a strong increase in SLC12A1 expression: 
GBM62 in GSE16011 (identical to the sample used in this study) and GSM187196 in 
GSE7696. A further two samples show a more modest expression: Grade II astrocytoma 
134 in GSE16011 and HF1708 in the Rembrandt data set. It remains to be determined 
whether the increased SLC12A1 expression in these samples is due to genomic changes. 
SLC12A1 is a Na–K–Cl cotransporter that mediates active reabsorption of sodium-
chloride in the thick ascending limb of the loop of Henle in the kidney (Quaggin et al., 
1995). It is interesti ng to note that the coiled-coil dimerization do main of SLC12A1 is 
preserved in the fusion protein. Such dimerization domains have been observed in se-
veral oncogenic fusion proteins (Houtman et al., 2007; Soda et al., 2007) and can cause 
a constitutive activation of the fusion part ners. LEO1 is part of the PAF1 protein com-
plex that associates with the RNA polymerase II subu nit POLR2A (Rozenblatt-Rosen et 
al., 2005). LEO1 interacts with b-catenin in the Wnt path way (Mosimann et al., 2006; 
Chaudhary et al., 2007), a known oncogenic pathway in colon carci nomas. Although the 
functional consequences of the LEO1-SLC12A1 fusion gene remains to be determined, it 
is interesting to note that delayed senescence, increased proliferation, and life span ex-
tension is observed in cells expressing LEO1, lacking the COOH-terminal domain (Zhao et 
al., 2005). Interestingly, a LEO1 COOH-terminal truncation is one of the consequences of 
the LEO1-SLC12A1 fusion product. However, the observation that no additional samples 
were iden tified with genomic changes in SLC12A1 or LEO1 and that only few samples 
show aberrant SLC12A1 expression indicates that the LEO1/SLC12A1 fusion gene is not 
a recurrent event in gliomas. 
In summary, we have performed integrated genomic profiling on 21 GBMs and 19 
ODs. We have identified RBBP5, a member of the RB pathway, as a novel candidate onco-
gene in GBMs. In addition, by screening for aberrant exon expression levels in genes that 
reside over chromosomal breakpoints, we identified a fusion gene between LEO1 and 
SLC12A1. Our data therefore show that integrated genomic profiling can identify novel 
genes involved in tumor initia tion and/or progression and can be used as an approach to 
identify novel fusion genes. 
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Abstract
Genomic translocations have been implicated in cancer. In this study, we performed a 
screen for genetic translocations in gliomas based on exon-level expression profiles. We 
identified a translocation in the contactin associated protein-like 2 (CASPR2) gene, enco-
ding a cell adhesion molecule. CASPR2 mRNA was fused to an expressed sequence tag 
that likely is part of the nuclear receptor coactivator 1 gene. Despite high mRNA expres-
sion levels, no CASPR2 fusion protein was detected. In a set of 25 glioblastomas and 22 
oligodendrogliomas, mutation analysis identified two additional samples with genetic 
alterations in the CASPR2 gene and all three identified genetic alterations are likely to 
reduce CASPR2 protein expression levels. Methylation of the CASPR2 gene was also ob-
served in gliomas and glioma cell lines. CASPR2-overexpressing cells showed decreased 
prolif eration rates, likely because of an increase in apoptosis. Moreover, high CASPR2 
mRNA expression level is positively correlated with survival and is an independent prog-
nostic factor. These results indicate that CASPR2 acts as a tumor suppressor gene in 
glioma. 
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Introduction 
Gliomas are the most frequently diagnosed type of primary brain tumor in adults, with an 
incidence of E3.5/100 000 (http://www.cbtrus.org). Depending on the cell type they res-
emble, gliomas can be subdivided histologically into astrocytomas (As), oligodendroglio-
mas (ODs) and oligoastrocytomas (OAs), the latter exhibiting features of both astrocytes 
and ODs. Gliomas can be further subdivided into various grades of malignancy (II–IV), 
with grade IV tumors (glioblasto mas (GBMs)) being the most common and malignant. 
GBMs can occur de novo (primary GBM) or evolve from lower-grade gliomas (secondary 
GBM). Despite extensive therapy (a combination of surgery, radiation and/or chemothe-
rapy), all grade II–IV gliomas are eventually fatal, with a median survival time ranging 
from over 10 years (grade II ODs) to less than 1 year in GBM (Ohgaki and Kleihues, 2005; 
Louis et al., 2007). 
Causal genetic changes in cancer cells are direct targets for treatment. In GBM, the 
most frequently affected genes include CDKN2A (50%), EGFR (37%), TP53 (40%) and 
PTEN (30%) (Parsons et al., 2008). In lower-grade gliomas, frequent alterations are a 
loss of heterozygosity on 1p and 19q (Kraus et al., 1995), and the recently discovered 
IDH1 mutations (Balss et al., 2008; Gravendeel et al., 2009; Yan et al., 2009). Although 
frequently mutated causal genes have been found, treatments aimed at the molecular 
changes have thus far had limited success in glioma. To provide new targets for therapy, 
tumorigenesis has to be understood at the molecular level, and new causal genes and 
pathways have to be identified. 
Genomic translocations that result in the expression of a fusion gene have been im-
plicated in cancer. As such translocations often show aberrant expression of the fusion 
partners, screening for aberrant expression can identify novel fusion genes (Tomlins et 
al., 2005). Exon level expression profiling is a method that can identify differentially ex-
pressed splice variants (Clark et al., 2007; French et al., 2007). We have recently shown 
that genomic mutations in cancer that lead to skipping of one or more exons are also 
detected by such arrays (Schutte et al., 2008). Aberrant expression of exons also occurs 
when translocations lead to a gene fusion and exons from one gene are driven by a 
promoter from another gene. We therefore screened for such transloca tions based on 
exon array data. 
Our screen identified the contactin-associated protein like 2 (CASPR2) gene, enco-
ding a cell adhesion molecule, as the 3'fusion partner of a translocation. In a set of 25 
GBMs and 22 ODs, we additionally identified one intragenic deletion and one larger de-
letion that includes the entire CASPR2 gene. All three identified genetic alterations are li-
kely to reduce CASPR2 protein expression levels. CASPR2 methylation was also observed 
in gliomas and glioma cell lines. Interestingly, a significant decrease in proliferation rate 
was observed in cells overexpressing CASPR2-green fluorescence protein (GFP). In addi-
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tion, high CASPR2 expression is associated with longer survival, and multivariate analysis 
indicated that CASPR2 mRNA expression level is an independent prognostic factor. The 
genetic alterations identified, the reduced proliferation rate of CASPR2-GFP-expressing 
cells and the positive correla tion between CASPR2 expression and survival indicate that 
CASPR2 acts as a tumor suppressor gene in glioma. 
Results 
Identifying a novel translocation involving EST AI364529 and CASPR2 
We have recently demonstrated that exon-level profiling can detect exon-skipping mu-
tants and splice variants (French et al., 2007; Schutte et al., 2008). In this study, we used 
these expression profiles to screen for fusion transcripts. We first identified transcripts 
with aberrant expression ratios between 5'
 
and 3'
 
exons in 25 GBMs and 22 ODs (see Ma-
terials and methods). Eleven genes were found in which the 5'/3'
 
ratios differed 416-fold 
from the mean (see for example Figure 1a and Supplementary Table 3). Visual inspection 
reduced the number of candidates by eliminating those with, for example, one aberrant 
probeset expression or those with a highly skewed 5'/3'expression ratio in all samples. 
In several of the identified candidates, the altered 5'
 
expression was likely caused by 
transcripts derived from an alternative promoter (data not shown). Transcripts driven 
from an alternative promoter will also have an altered 5'/3'
 
expression ratio, and the 
identification of such transcripts validates our approach. 
In GBM142, 5'
 
RACE-PCR identified a candidate fusion gene between exon 9 of 
CASPR2 and an expressed sequence tag (EST AI364529) located on chromosome 2. 
The EST AI364529–CASPR2 fusion gene was confirmed by reverse transcriptase–PCR 
using a forward primer in EST AI364529 and a reverse primer in CASPR2 (Figure 1b). 
EST AI364529 is located upstream of the nuclear receptor coactivator 1 (NCOA1) gene. 
Sequence alignment suggests that, similar to mouse Ncoa1, this EST forms part of the 
human NCOA1 gene (Figure 1c). The translocation does not appear to affect expression 
of the NCOA1 gene in GBM142 (Figure 1d). Apparently, the remaining allele is sufficient 
to drive normal NCOA1 expression levels. The observation that NCOA1 expression is not 
altered led us to focus our further experiments on the CASPR2 gene. 
Genomic translocations in cancer can result in expression of fusion proteins that act 
as oncogenes (Heisterkamp et al., 1985; Tomlins et al., 2005). However, western blot 
failed to detect expression of the AI364529–CASPR2 fusion protein (Figure 2). Thus, in 
spite of high transcript expression levels (Figure 1a); no protein product appears to be 
expressed. The absence of protein expression may be explained by the absence of a 
clear translation initiation codon with a consensus Kozak sequence in the fusion trans-
cript. The absence of an EST AI364529–CASPR2 protein expression in GBM142 suggests 
that the fusion protein does not act as an oncogene. 
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Mutation screen in CASPR2 
Causative genetic changes in cancer often have a significant mutation frequency. We 
therefore screened for additional mutations in the CASPR2 gene. We first determined 
whether the specific EST AI364529– CASPR2 translocation occurs in other tumor sam-
ples. Using a forward primer in EST AI364529 and a reverse primer in CASPR2, reverse 
transcriptase–PCR failed to identify this specific translocation in 25 GBMs (Figure 3a). 
We then analyzed all exon-expression profiles in detail (25 GBMs and 22 ODs) to iden-
tify other candidate breakpoints within the CASPR2 gene. Such candidates may have 
escaped detection in our initial screen because of focusing on top candidates. In another 
sample (GBM96), the 5'/3'
 
exon expression also shows an aberrant ratio (Figure 3b). 
However, such profile can be expected when CASPR2 expression is derived from the 
alternative promoter present between exons 21 and 22 (CR933671). CASPR2 protein ex-
pressed from this alternative promoter contains only the last three coding exons and, on 
the protein level, lacks the extracellular domain. This isoform of CASPR2 apparently does 
not function as a cell adhesion molecule and may compete with expression of full-length 
CASPR2 (for protein expression in GBM96, see Figure 2b). 
We then performed mutational analysis of all 24 coding exons of CASPR2 in 23 GBMs 
and 18 ODs (Supplementary Table 4). One heterozygous missense mutation in GBM139 
(73 G-A) was identified (Figure 3c). This base change causes an alanine amino acid to be 
replaced by a threonine (A24T). The mutation lies in exon 1, within the conserved region 
coding for the signaling peptide of CASPR2. The base change is not present in single-
nucleotide polymorphism databases, but was present in DNA isolated from the patients’ 
blood sample, indicating that the mutation is not somatic. Western blot detected very 
low protein expres sion in GBM139 (Figure 2b). 
We next screened for changes in CASPR2 copy number in the same sample co-
hort. Copy number changes were inferred from genotyping arrays (Bralten et al., 2010). 
As reported previously (Bredel et al., 2005; Freire et al., 2008), trisomy of the entire 
chromosome 7 was frequently observed in gliomas. However, in GBM254, genotyping 
identified a heterozygous deletion of a large region including the entire CASPR2 gene 
(chr7:102106439–end, Figure 3d). Interestingly, in OD53, genotyping also identified an 
intragenic deletion (chr7:146208141–147249840, Figure 3d) that spans exons 4–14 and 
will result in a premature termination codon in exon 15. No mutations were found in the 
coding exons of the remaining CASPR2 allele. However, both GBM254 and OD53 had 
low CASPR2 mRNA expression (Supplementary Figures 1 and 2) and no CASPR2 protein 
expression (Figure 2c). 
As intronic CASPR2 deletions have been associated with schizophrenia and epilepsy 
(Friedman et al., 2008), intronic deletions may affect CASPR2 function. We therefore 
screened for small intronic deletions in four samples (in which no base change or large 
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deletion was identified), using custom-made genotyping arrays that span the entire 
CASPR2 gene. Custom arrays confirmed the trisomy on chromosome 7 in GBM157 in the 
CASPR2 region. No additional genetic changes were identified using these arrays (data 
not shown). 
As CASPR2 is methylated in pancreatic carcinoma (Omura et al., 2008), we deter-
mined the CASPR2 methylation status of six cell lines (U87, U118, U138, U373, T98 and 
human embryonic kidney (HEK)) and seven tumor samples. In all glioma cell lines, the 
CASPR2 gene was methylated and all these cell lines have low CASPR2 mRNA expres-
sion. The CASPR2 gene is not methylated in HEK cells, which may explain CASPR2 mRNA 
Figure 1 Identification of an EST AI364529–CASPR2 translocation. (a) The RMA expression levels (y 
axis) of all probesets of the CASPR2 gene (x axis) in GBM142 (red line) and mean CASPR2 expres-
sion of controls (ctr; n =6, blue), glioblastomas (n =24, purple) and oligodendrogliomas (n =22, 
green). In GBM142, the expression of exons 1–8 is B100-fold lower than the expression of exons 
9–24. Values are shown as ±s.e. (b) Sequence of the translocation region. Upper panel: the CASPR2 
reference sequence. Lower panel: sequence data of the EST AI364529–CASPR2 fusion gene. (c) 
Graphical representation of the EST AI364529–CASPR2 fusion gene. (d) NCOA1 expression levels 
in GBM142 (red line) does not appear to be affected by the EST AI364529–CASPR2 gene fusion. 
GBM142 expression is similar to the mean expression of controls (n =6, blue), glioblastomas (n 
=24, purple) and/or oligodendrogliomas (n =22, green). 
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Figure 2 CASPR2 protein expression. (a) Western blot of protein lysates derived from GBM163, 
GBM142 and a control brain sample. Note that GBM142 does not express any alternative-sized 
CASPR2 protein. In this western blot, an equal amount of protein was loaded as used for (b). 
(b) Western blot of CASPR2. Top panel: CASPR2, expected size 148 kDa. Lower panel: Tubulin-a 
(a-tub), expected size 50 kDa. Numbers indicate individual samples. Non-neoplastic brain tissue 
(control) and rat cerebellum (rat cb) were used as controls. The EST AI364529–CASPR2 fusion gene 
therefore apparently does not result in fusion protein expression. (c) Western blot of CASPR2 of 
the two samples with heterozygous deletions (GBM254 and OD53) (see also Figure 3d) and two 
control brain samples. Both samples do not express CASPR2. (d) Immunocytochemical staining of 
GBM163 and GBM207 demonstrates that CASPR2 and GFAP are expressed by the tumor. 
194
116
97
50
37
29
20
G
BM
16
3
G
BM
14
2
ct
r
194
116
50
CASPR2
α-tub
ct
r
G
BM
 20
7
G
BM
16
4
G
BM
16
1
G
BM
67
G
BM
61
G
BM
60
G
BM
20
6
CASPR2
α-tub
194
116
50
ra
t c
b
ct
r
G
BM
13
9
G
BM
14
2
G
BM
96
G
BM
15
2
G
BM
16
3
α-tub
194
116
50
CASPR2
ct
r1
G
BM
25
4
O
D5
3
ct
r2
CASPR2 GFAP DAPI CASPR2  + GFAP
GBM 207
GBM 163
70
Chapter 4
expression in these cells (GSE1309). However, western blot analysis failed to detect CA-
SPR2 protein expression in HEK cells (data not shown). Four out of seven tumor samples 
had CASPR2 methylation, and methylation status correlated with mRNA expres sion in 
five out of seven samples. Methylation of the CASPR2 gene, therefore, may be an epige-
netic mechan ism that downregulates CASPR2 expression in gliomas. 
In summary, our comprehensive mutational analysis identified at least three genetic 
changes in the CASPR2 gene in gliomas: one translocation, one intragenic deletion and 
one larger deletion in a set of 47 glioma samples. In addition, CASPR2 functioning may 
also be compromised in GBM96, where expression might be driven from an alternative 
promoter. The CASPR2 gene is also methylated in a subset of gliomas. At least several of 
the identified mutations appear to disrupt normal CASPR2 functioning. 
CASPR2 overexpression decreases the proliferation rate 
The relatively high frequency in which we identified genetic changes in the CASPR2 gene 
led us to perform functional experiments to determine the role of CASPR2 in glioma 
formation and/or progression. We first created a CASPR2 construct with a hemagglutinin 
(HA) epitope inserted directly c-terminal of the signaling peptide domain and enhanced-
GFP inserted intracellu larly, following the transmembrane domain (Supple mentary Fi-
gure 3). The final HA-CASPR2-GFP construct allowed us to use the extracellular HA tag 
to confirm transmembrane localization using immunocy tochemistry (Supplementary 
Figure 4). The intracellular GFP tag allowed visualization of the construct in live cells 
while preserving functioning of the intracellular CASPR2 domain (Horresh et al., 2008). 
The construct was then used to create stable HA-CASPR2-GFP expressing U87MG, U373 
and HEK cell lines. 
U87MG and HEK cells stably expressing HA CASPR2-GFP showed a decrease in prolife-
ration rate compared with control (DsRed2) expressing cells in a WST-1 cell proliferation 
assay. The mean reduction in proliferation rate was 13% (range 7.3–22.2%, P =0.007). 
This reduction appears to be specific for CASPR2 as other overexpressed enhanced green 
fluor escent protein fusion genes, in our laboratory do not show a decreased proliferati-
on (LBC Bralten and PJ French, data not shown). We also analyzed co-cultures of U87MG 
cells that initially contained a mixture of HA-CASPR2-GFP-and DsRed2-expressing cells 
(see Materials and methods). Cell cycle analysis of the mixture shows a much lower G2 
peak in the HA CASPR2-GFP-expressing cells compared with the DsRed2-expressing cells 
(Figure 4a). After 9–10 cell culture passages, the number of HA-CASPR2-GFP expressing 
cells in three independent experiments was reduced to 0.3, 0.3 and 4.5%, respectively, 
of the total number of cells (Figure 4b). Fluorescence activated cell sorting (FACS) ana-
lysis on U87MG mixed cell cultures therefore confirmed the reduced proliferation as 
observed in our WST-1 cell proliferation assays. 
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Figure 3 CASPR2 analysis. (a) The EST AI364529(exon 1)–CASPR2(exon 9) translocation is unique 
in a cohort of 25 glioblastomas. RT–PCR only detects a specific fusion gene in GBM142 and not in 
other samples. Control (Ctr): non-neoplastic brain tissue. (b) A high expression of the last five pro-
besets in GBM96 was observed compared with control brain samples (n =6, blue), glioblastomas 
(n =24, purple) and oligodendrogliomas (n =22, green). GBM142 is shown in red. The high expres-
sion of 3'exons of GBM96 could be because of expression by an alternative promoter. (c) A single 
base change 73G4A, resulting in an alanine to be replaced by threonine (A24T), was identified in 
GBM139 (lower panel). The mutation lies in exon 1, within the conserved region coding for the 
signaling peptide of CASPR2 (upper panel: reference sequence). (d) Genotyping identified 2/40 
samples with allelic loss of the CASPR2 gene. In GBM254, a large heterozygous loss including the 
CASPR2 gene was identified (chr7:102106439–end). In OD53, a heterozygous intragenic deletion 
was identified corresponding to a deletion of exons 4–14 (chr7:146208141–147249840). A full 
colour version of this figure is available at the Oncogene journal online. 
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To determine the effects of CASPR2 overexpression HA-CASPR2-GFP-expressing cells 
(U118: 94.9 vs on cell proliferation in other cell lines, U118, U138, 1.5%; U138: 57.6 vs 
0.7%; U373: 51.8 vs 5.4%; T98: U373, T98 and HEK cells were transfected with HA-9.9 vs 
1.3%; HEK: 94.9% vs 18.1%; P =0.007). These CASPR2-GFP or DsRed2. After 3 weeks of 
culture on differences are in line with the hypothesis that selection medium, the percen-
tages of DsRed2-expressing HA-CASPR2-GFP-expressing cells have a growth cells were 
significantly higher than those of the disadvantage. 
FACS analysis showed a lower percentage of cells that have entered the cell cycle (S-, 
G2-and M-phase) in the HA-CASPR2-GFP-expressing U87MG, U373 and HEK cells com-
pared with DsRed2-expressing cells (20.4 vs 29.0% (P =0.0044), 18.8 vs 21.9% (P =0.077) 
and 20.5 vs 28.6% (P =0.014), respectively; other cell lines not determined). 
The absence of CASPR2 expression in established cell lines (U87MG, U118, U138, 
U251, U373, U387, SF126, SF268, SF539, A172, SNB19, SNB75, LN229 and T98), accor-
ding to the GEO datasets (GSE10547, GSE5720 and GSE4536), prohibited knockdown 
experiments. 
We next aimed to determine the mechanism of the CASPR2-associated decrease in 
proliferation rate. b-Galactosidase assays did not reveal a difference in cellular senes-
cence between U87MG cells expressing HA-CASPR2-GFP and DsRed2 (1.26% and 1.48%, 
respectively, P =0.63). The HA-CASPR2-GFP-expres sing cells do not show a marked incre-
ase in cell volume compared with the DsRed2-expressing cells, arguing against increased 
CASPR2-associated cellular senes cence (Supplementary Figure 5). However, a 46% in-
Figure 4 FACS analysis of a mixed population (equal amounts) of U87MG cells stably expressing 
DsRed2 or HA-CASPR2-GFP. (a) Cell cycle analysis (passage 1). The red graph depicts the DsRed2-
expressing cells, the green graph the HA-CASPR2-GFP expressing cells, dark green represents the 
overlap of the two graphs. Note the much lower G2 peak in the HA-CASPR2-GFP expressing cells. 
(b) After nine passages, the number of HA-CASPR2-GFP cells was reduced to 0.3% of the total cell 
population, indicating that HA-CASPR2-GFP-expressing U87MG cells have a reduced proliferation 
rate. 
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crease in apoptosis was observed in HA-CASPR2 GFP-compared with DsRed2-expressing 
U87MG cells (P =0.0019). This increase in apoptosis in CASPR2-overexpressing cells may 
therefore explain the CASPR2-associated reduction in proliferation. 
CASPR2 overexpression does not affect migration and invasion 
Cell adhesion molecules, like neural cell adhesion molecule, are thought to have a role 
in invasiveness and progression in cancer (Zecchini and Cavallaro, 2010). As CASPR2 also 
functions as a cell adhesion molecule, we determined whether CASPR2 expression may 
affect cell migration and invasion. No difference in migration and invasion of U87MG cell 
lines was observed both by Millipore migration and invasion assays (Millipore, Bill erica, 
MA, USA; P =0.25 and 0.38, respectively) and in the Incucyte (migration only) (P =0.91). 
CASPR2 expression is positively correlated with patient survival 
As CASPR2-overexpressing tumor cells in vitro have a decreased cell proliferation, we 
looked at survival and CASPR2 mRNA expression in a set of 268 glial brain tumors. CA-
SPR2 mRNA expression was positively correlated with overall survival (Figures 5a and 
b). Patients with low CASPR2 expression (less than the median) had a median survi-
val of 0.79 years compared with 2.83 years in the group with high CASPR2 expression 
(Po0.0001). Even within defined histological subgroups (AIII, AOIII and ODIII), patients 
with high CASPR2 expression (greater than the median) had a significantly better survi-
val than patients with low CASPR2 expression (less than the median) (P =0.0197, 0.0371 
and 0.0001, respectively). Similarly, the survival of GBM patients with high CASPR2 ex-
pression (top 25th percentile) was significantly longer than that of other GBM patients 
(P =0.00451) (Supplementary Figure 6 and Supplementary Table 5). No difference in sur-
vival was observed in tumors with high expression of glial (GFAP) or neuronal (NEFH 
Table 1 Multivariate analysis including age, Karnofsky performance score, diagnosis and CASPR2 
mRNA expression 
HR s.e.m. z P>z 95% CI 
Age 1.03045 0.00568 5.44 <0.001 1.019378 1.041642 
KPS 0.992927 0.002582 -2.73 0.006 0.98788 0.998 
PA 0.719409 0.030271 -7.83 <0.001 0.662461 0.781253 
CASPR2 0.713202 0.091988 -2.62 0.009 0.553892 0.918333 
CASPR2 expression 
Abbreviations: CASPR2, contactin-associated protein-like 2; CI, confidence interval; HR, hazard ra-
tio; KPS, Karnofsky performance score; PA, diagnosis. 
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or NEFM) markers excluding the possibility of low tumor content in gliomas with high 
CASPR2 expression (Supplementary Figure 7 and Supple mentary Table 6). Furthermore, 
CASPR2 immuno cytochemistry on GBM163 and GBM207 confirmed that CASPR2 is ex-
pressed by tumor cells and is not due to a contamination of non-neoplastic brain tissue 
(Figure 2d). 
Multivariate analysis demonstrated that CASPR2 expression is a prognostic factor 
that is independent of histological diagnosis (including subtype and grade), age and Kar-
nofsky performance score (P =0.009) (Table 1). 
Figure 5 CASPR2 expression is positively correlated with patient survival. (a) Kaplan–Meier survival 
plots of patients with high (greater than the median, gray line) and low CASPR2 expression (lesser 
than the median, black line) in a cohort of 268 glioma patients. CASPR2 expression is positively 
correlated with overall survival (2.83 vs 0.79 years, Po0.0001). (b) CASPR2 mRNA expression in dis-
tinct histological glioma subgroups and eight control samples. Horizontal bars represent the medi-
an of each subgroup. Non neoplastic brain tissue has the highest CASPR2 mRNA expression levels. 
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Discussion 
In this paper, we describe a novel translocation involving the CASPR2 gene using exon-
expression arrays. CASPR2 was fused with an EST (EST AI364529) that is likely to be part 
of the NCOA1 gene. The fusion of this EST and CASPR2 resulted in loss of CASPR2 pro-
tein expression, despite high mRNA expression. Mutation analysis of CASPR2 revealed at 
least two other glioma samples with inactivating mutations. Methylation of the CASPR2 
gene was also observed in gliomas and glioma cell lines. Furthermore, lower prolifera-
tion rates were observed after CASPR2 overexpression in glioma cell lines, most likely 
due to an increase in apoptosis in these cells. Finally, multivariate analysis showed that 
high CASPR2 expression is positively correlated with patient survival. Our results are 
consistent with CASPR2 functioning as a tumor suppressor gene in gliomas. 
The CASPR2 gene spans a region of 2.3 Mb on chromosome 7. It encodes CASPR2, 
a transmembrane cell adhesion molecule and member of the neurexin superfamily. Ex-
tracellularly, CASPR2 binds to contac tin 2 (TAG-1), a neural recognition protein of the 
immunoglobulin cell adhesion molecule superfamily (Poliak et al., 2003). The CASPR2–
contactin 2 complex is involved in clustering of K+
 
channels in the juxtaparanodal region 
of the nodes of Ranvier (Poliak et al., 2003) and in neurite outgrowth (Lieberoth et al., 
2009). Germline genetic alterations in the CASPR2 gene have been found in several neu-
rological and psychiatric diseases, including recessive symptomatic focal epilepsy and 
autism (Strauss et al., 2006; Bakkaloglu et al., 2008; Jackman et al., 2009), combined 
schizophrenia and epilepsy (Friedman et al., 2008) and Gilles de la Tourette’s syndrome 
with obsessive–compulsive disor der (Verkerk et al., 2003). All genetic alterations found 
were inactivating. Furthermore, linkage studies have identified single-nucleotide poly-
morphisms in CASPR2 that predispose for autism (Alarcon et al., 2008; Arking et al., 
2008) and language impairments (Vernes et al., 2008). These studies emphasize the im-
portance of CASPR2 in the central nervous system. 
Several other studies have highlighted a potential role of CASPR2 in cancer forma-
tion and/or progression. First, Thorell et al. suggest CASPR2 to be a tumor suppressor 
gene; they show a fivefold lower CASPR2 expression in unfavorable neuroblastomas 
compared with favorable neuroblastomas (Thorell et al., 2009). CASPR2 was the gene 
with the largest change in expression found between these two groups (Thorell et al., 
2009). Second, CASPR2 is a common integration site of the sleeping-beauty transposon 
in sarcomas from Arf-/-mice (Collier et al., 2005). In three independent sarcomas, the 
transposon disrupted the coding sequence of CASPR2 (Collier et al., 2005). Finally, CA-
SPR2 is methylated in 82% (47/57) of the pancreatic cancers, compared with 3% (1/34) 
of the cases of normal pancreas tissue (Omura et al., 2008). In our group of 268 gliomas, 
CASPR2 expression was heterogeneous (Figure 5b) and methylation of the CASPR2 gene 
could in part be an explanation for the remaining low expressing samples. More genera-
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lly, the CASPR2 gene is part of a common fragile site (McAvoy et al., 2007). Such fragile 
sites are frequently disrupted in cancer and are thought to contain tumor suppressor 
genes (Smith et al., 2007). In summary, disruption of the CASPR2 gene has been reported 
in several cancer subtypes, as well as in various neurological and psychiatric disorders. 
Disruptive genetic changes were also identified in the present study. 
With its intracellular domain, CASPR2 binds to the 4.1B protein (Denisenko-Nehrbass 
et al., 2003), which is also known as DAL-1 (Differentially expressed in Adenocarcinoma 
of the Lung). DAL-1 is a member of the protein 4.1 family and acts as a tumor suppressor 
in meningiomas (Gutmann et al., 2000). Another well known member of the protein 4.1 
family in brain cancer is schwannomin (merlin), the product of the NF2 tumor suppres-
sor gene. Loss of heterozygosity of the DAL-1 region was found in 39% of gliomas (Tran 
et al., 1998). DAL-1 forms a functional complex with CASPR2. This complex is thought to 
be involved in cell signaling through the activation of c-Jun amino-terminal kinase, a re-
gulator of the retinoblastoma protein (Gerber et al., 2006). The mechanism of action of 
CASPR2 as a tumor suppressor gene may be similar to that of DAL-1. Apparently, CASPR2 
is part of a complex that, when inactivated, is involved in tumorigenesis. 
CASPR2 is predominantly expressed in cells of neuronal origin (Poliak et al., 1999; 
Lieberoth et al., 2009). As gliomas are thought to be of non-neuronal origin, we exa-
mined whether the CASPR2 protein is also expressed in glial cells. Immunocytochemis-
try, using antibodies against CASPR2 and the glial marker GFAP or Vimentin on primary 
cultured rat hippocam pus, indeed confirmed that a subpopulation of glial cells (7 and 
4%, respectively) express CASPR2 (Supplementary Figure 8). In whole rat brain, howe-
ver, CASPR2 and GFAP expression are seldomly colocalized (Supplementary Figure 9). As 
CASPR2 is expressed in a subset of cultured rat hippocampal glial cells and in certain glio-
mas, it is possible that certain gliomas originate from or dediffer entiate in the direction 
of this subpopulation of glial cells. 
NCOA1, the 5'
 
fusion partner of the translocation, has also been reported in cancer. 
NCOA1 is a transcriptional co activator for steroid and nuclear hormone receptors. In 
GBM NCOA1 is a frequent breakpoint (Freire et al., 2008), and in alveolar rhabdomyosar-
coma NCOA1 was reported as an alter native for FKHR as a translocation partner of PAX3 
(Wachtel et al., 2004). These data indicate that the NCOA1 region is a site with genomic 
instability in cancer. However, the translocation does not affect the expression of NCOA1 
(Figure 1d), which suggests that NCOA1 does not have a role in our sample cohort. 
Although our method of detecting translocations proved to be successful, rigorous 
testing remains to be done. However, compared with other ways of screening for gene 
rearrangements (Tomlins et al., 2005; Maher et al., 2009), our method may provide a 
cost-effective alternative that does not require large amounts of sample or depend on 
large-sample cohorts. 
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In summary, the absence of protein expression resulting from the translocation in 
GBM142, the intragenic deletion in OD53, the reduced proliferation rate of CASPR2-
expressing cells and the positive correlation between CASPR2 expression and survival 
indicates that CASPR2 functions as a tumor suppressor gene in gliomas 
Materials and methods 
Sample collection 
All glioma samples were derived from patients diagnosed between 1988 and 2004 
and treated at the Erasmus Medical Center. All histological diagnoses were made on 
formalin fixed, paraffin-embedded hematoxylin and eosin-stained sec tions by an expe-
rienced neuropathologist (JMK) (Kleihues and Cavenee, 2000). Samples were collected 
immediately after surgical resection, snap-frozen and stored at -80 1C. All samples were 
visually inspected on 5-mm paraffin-embedded hematoxylin and eosin-stained frozen 
sections by the neuro pathologist (JMK) to ensure 470% tumor content. Use of material 
was approved by the Institutional Review Board. Non-diseased adult cortical brain sam-
ples were obtained from the Erasmus University Medical Center (n =4) and the Dutch 
Brain Bank (n =3) or purchased (n =1; Qiagen, Venlo, The Netherlands) as described 
(Gravendeel et al., 2009). 
RNA, DNA and protein isolation 
Tissues adjacent to the paraffin-embedded hematoxylin and eosin-stained frozen sec-
tions were used for nucleic-acid isolation as described (French et al., 2007). For this 
study, we also isolated protein from the Trizol fraction according to the manufacturer’s 
protocol (Invitrogen, Breda, The Nether lands). RNA quality was assessed on a Bioanaly-
ser (Agilent Technologies, Amstelveen, The Netherlands). High-quality RNA (that is, RNA 
integrity number 47.0; Schroeder et al., 2006) was used for our experiments. All genomic 
DNA was amplified using a REPLI-g mini kit (Qiagen). 
Arrays 
Identification of translocation candidates made use of exon level expression profiles re-
ported in French et al. (2007) and Schutte et al. (2008). This dataset, GSE9385, consists 
of 26 GBMs, 22 ODs and 6 control samples. CASPR2 copy number was inferred from ge-
notyping arrays performed on 21 GBMs and 19 ODs using 250k NspI arrays (Affymetrix, 
Santa Clara, CA, USA) (Bralten et al., 2010). Survival analysis made use of clinical data 
and expression profiles from a cohort of 268 glioma samples (GSE16011: 117 GBM, 30 
AIII, 23 AOIII, 45 ODIII, 16 AII, 7 AOII, 19 ODII and 11 AI; Supplementary Table 1) on U133 
plus 2.0 arrays (Affymetrix) described in Gravendeel et al. (2009). Ultra-high resolution 
78
Chapter 4
copy number variation analysis of a 2.91-Mb genomic region containing the complete 
CASPR2 gene was performed on four samples (GBM56, GBM96, GBM142 and GBM157) 
using a custom NimbleGen microarray (Roche NimbleGen Systems, Madison, WI, USA). 
The average probe distance for this region was 23 bp. 
Identification of fusion genes 
The signal intensity estimate and the P-value for each probeset were extracted from the 
Human Exon 1.0 ST arrays in Affymetrix genotyping console software using RMA. We 
then screened for candidate fusion genes based on aberrant expression ratios between 
5'
 
and 3'
 
exons. We first excluded exons with low expression levels in all samples (that is, 
expression levels o6.5). We then excluded exons that show poor correlation with the es-
timated transcript expression level (metaprobeset level), that is, those with a correlation 
o0.65. We then calculated the average ratio between the two 5'
 
and two 3'
 
probesets. 
Ratios deviating 416-fold from the median ratio were marked as strong candidate fusion 
partners. All remaining candidates were visually inspected for aberrant expression. 
5'
 
and 3'
 
rapid amplification of cDNA ends (RACE)-PCR was performed using the Ma-
rathon RACE Kit (Clontech, Mountain View, CA, USA) according to the manufacturer’s 
protocol. All primers were from Invitrogen and were designed using Primer3 (biotools.
umassmed.edu/bioapps/primer3_www. cgi) (Supplementary Table 2). 
Western blotting 
Approximately 2 mg protein was loaded onto 10% polyacry lamide gels, and blotted onto 
a Hybond-C super nitrocellulose membrane (Amersham Biosciences, Roosendaal, The 
Nether lands). Membranes were incubated in rabbit-anti-CASPR2 polyclonal antibody 
(Chemicon International, Temecula, CA, USA) (1:1000) or mouse-anti-tubulin monoclo-
nal antibody (Sigma, St Louis, MO, USA) (1:3000). Membranes were then incubated with 
either horseradish peroxidase-conjugated polyclonal swine-anti-rabbit (Dako, Glostrup, 
Denmark) (1:2500) or polyclonal rabbit-anti-mouse (Dako) (1:2500). Detection was car-
ried out using the Amersham ECL advance western blotting detection kit (GE Healthcare, 
Diegem, Belgium). 
PCR amplification and bisulfite sequencing 
All 24 coding exons of CASPR2 were amplified by PCR in 23 GBMs and 18 ODs. The se-
quence could be evaluated in a total of 527/552 and 318/432 exons in GBMs and ODs, 
respectively. In 25 GBMs a PCR was performed with a forward primer designed in EST 
AI364529 and a reverse primer designed in exon 9 of CASPR2. Primers and PCR conditi-
ons are listed in Supplementary Table 2. Genomic DNA of six cell lines (U87MG, U118, 
U138, U373, T98 and HEK) and seven glioma samples (four GBM, three ODIII), extrac-
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ted using Qia-amp DNA mini kits (Qiagen), was bisulfite treated using the MethylEasy 
DNA Bisulphite Modification Kit (Human Genetic Signatures, Sydney, New South Wales, 
Australia) according to the manufacturer’s protocol. Samples with 425% methylation on 
evaluable CpG island were considered methylated. PCR primers and conditions to deter-
mine CASPR2 methylation were performed as described (Omura et al., 2008). Amplified 
products were sequenced using the Big Dye Terminator v3.1 (v1.1 for bisulfite-treated 
samples) Cycle Sequencing Kit (Applied Biosystems, Nieuwe kerk a/d IJssel, The Nether-
lands). Samples were analyzed using Mutation Surveyor V2.51 (SoftGenetics, State Col-
lege, PA, USA). 
Constructs 
CASPR2 cDNA (Origene Technologies, Rockville, MD, USA) was fused to HA and GFP as 
outlined in Supplementary Figure 1. Our construct preserved the N-terminally localized 
signal peptide and the C-terminally located PDZ domain (see also Horresh et al., 2008). 
Primers and conditions are stated in Supplementary Table 2. HA-CASPR2-GFP was cloned 
into the pcDNA3.3-TOPO vector (Invitrogen). The control con struct consisted of the Ds-
Red2 gene cloned into the pcDNA3.3-TOPO vector. 
Cell lines 
U87MG, U118, U138, U373, T98 and HEK cells (American Type Culture Collection, Ma-
nassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (GIBCO, Breda, 
The Netherlands) supplemented with 10% fetal calf serum and antibiotics (penicillin and 
streptomycin) at 37 1C, in a 5% CO2 humidified chamber. For each cell line two 10-cm Pe-
tri dishes were transfected with 15 mg HA-CASPR2-GFP or DsRed2 using FuGENE 6 (Ro-
che, Woerden, The Netherlands) or, in the case of HEK cells, Polyethylenimine ‘Max’ (Po-
lysciences, Eppelheim, Germany). After 2 days cell cultures were supplemented with 600 
mg/ml (U87MG) or 400 mg/ml (U118, U138, U373, T98 and HEK) Geneticin (Invitrogen). 
CASPR2 mRNA levels in the stable U87MG cell line were 1.7 times higher than the levels 
in control brain, as was determined by quantitative PCR using SYBR green PCR master 
mix (Applied Biosystems; French et al., 2005). CASPR2 expression levels were evaluated 
relative to GAPDH expression. All primers had an amplifica tion efficiency 480% (deter-
mined by serial dilution) and generated a single amplification product (determined by 
melting point analysis). 
FACS sorting and cell cycle analysis 
After 3 weeks in selection medium, HA-CASPR2-GFP and/or DsRed2 expressing U87MG 
(in triplicate), U373 and HEK cells were FACS sorted (FACSAria, BD Biosciences, San Jose, 
CA, USA) into wells containing 10 000 HA CASPR2-GFP cells, 10 000 DsRed2 cells, or a 
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mixture of 5000 HA-CASPR2-GFP cells and 5000 DsRed2 cells (U87MG cells only). Paral-
lel sorted cells were analyzed for sorting efficiency (496%) and stained with Hoechst 
33258 (Sigma) to analyze viability (480%). FACS-sorted cells were either isolated alive 
and stained with 20 mg/ml Hoechst 33342 (Sigma) for 20 min at 37 1C (U87MG) or fixed 
with 4% PFA and stained with 20 mg/ml Hoechst 33258 (Sigma) for 1 h at 37 1C. The 
mixture of stable U87MG cells was fixed in 75% ethanol. Ki-67 expression was detected 
using rabbit-anti-Ki67 (1:100) (Abcam, Cambridge, UK) and an antigen-presenting cell-
conjugated donkey-anti-rabbit antibody (1:200) (Jackson ImmunoResearch, Suffolk, UK). 
Assays 
U87MG cells expressing either HA-CASPR2-GFP or DsRed2 were plated in two 96-well 
plates in three different con centrations (200, 400 and 800 cells/well), in triplo, for all 
three independently sorted cell populations. HEK cells expressing either HA-CASPR2-GFP 
or DsRed2 were plated at 1000 cells/ well, in triplo, and the experiment was performed 
in duplo. The percentage of cells expressing HA-CASPR2-GFP or DsRed2 was determined 
using FACS (U87MG— HA-CASPR2-GFP: 26.1–69.5%, DsRed2: 69.6–99.1%; HEK—HA-CA-
SPR2-GFP: 47.9%, DsRed2: 97.4%). The cell proliferation reagent WST-1 (Roche) was ad-
ded (1:10) at either 4 h or 3 days after plating. Absorbance was measured in a microplate 
reader (Multiskan Ascent, Thermo Electron Corporation, Breda, The Netherlands) at 440 
nm every 30 min for 3.5 h. The WST-1 reaction is linear in this timeframe; therefore, the 
slope of the trend line of the absorbance data was used as a measure of viability. The 
relative increase in this slope after 3 days was used as a measure of proliferation. 24-Well 
Cell Migration and Invasion Assay Kits (both from Millipore) were used according to the 
manufacturer’s protocol on 0.5 x10
6 
stable and sorted U87MG cells for 3 days. Results 
were quantified by colorimetric reading at 560 nm. Migration was also determined using 
an Incucyte (Essen Instruments, Hertfordshire, UK), for 72 h, at one frame per hour. 
MTrackJ, a plug-in of the ImageJ software, was used to quantify cell movement. 
Apoptosis of stable and sorted U87MG cells was determined using the Cell Death 
Detection ELISA Kit (Roche) according to the manufacturer’s protocol. Thousand cells 
per well were plated in a 96-well plate and left for 3 days before the start of the proto-
col. The experiment was performed two times in triplo with two independently sorted 
sets of stable cell lines. Senescence was detected in U87MG cells using the Senescence 
b-Galactosidase Staining Kit (Cell Signaling, Bioke, Leiden, The Netherlands) according to 
the manufacturer’s protocol. Two independently sorted stable cell lines were grown on 
chamber glasses in duplo for 3 days and stained with 250 ml staining solution. 
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Immunocytochemistry 
Primary rat hippocampal E18 cell cultures, prepared as described in Jaworski et al. 
(2005), were fixed after 26 days in culture with 4% paraformaldehyde. In addition, sec-
tions of normal rat brain and two gliomas (GBM163 and GBM 207) with high CASPR2 
protein expression were fixed with ethanol. Cultures and sections were incubated with 
mouse-anti-GFAP monoclonal antibody (1:20 000) (Sigma) or mouse-anti-Vimentin mo-
noclonal antibody (1:200) (Sigma) and rabbit-anti-CASPR2 polyclonal antibody, at dilu-
tions of 1:100 for cultures and 1:2000 for sections (Chemicon International). To check 
for membrane localization of HA-CASPR-GFP, transfected U87MG cells were incubated 
with mouse-anti-HA (1:1000) (Abcam). Secondary antibodies used were Alexa Fluor 488 
goat-anti-rabbit IgG or Alexa Fluor 568 goat-anti-mouse, at dilutions of 1:2500 for cultu-
res and 1:400 for sections and extracellular staining (both from Invitrogen). Slides were 
mounted with Vectashield mounting medium containing DAPI (Vector Laboratories, Bur-
lingame, CA, USA). 
Survival analysis 
Kaplan–Meier survival analysis was performed with Graph-Pad Prism 5.0 (GraphPad 
Software, San Diego, CA, USA), using a log-rank (Mantel–Cox) test. Multivariate analysis 
using Cox regression and the Breslow method for ties was performed using STATA 11.0 
(StataCorp LP, College Station, TX, USA). 
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Abstract
Mutations in the gene encoding the isocitrate dehydrogenase 1 gene (IDH1) occur at a 
high frequency (up to 80%) in many different subtypes of glioma. In this study, we have 
screenedfor IDH1 mutations in a cohort of 496 gliomas. IDH1 mutations were most fre-
quently observed in low grade gliomas with c.395G>A (p.R132H) representing >90% of 
all IDH1 mutations. Interestingly, non-p.R132H mutations segregate in distinct histologi-
cal and molecular subtypes ofglioma. Histologically, they occur sporadically in classic oli-
godendrogliomas and at significantly higher frequency in other grade II and III gliomas. 
Genetically, non-p.R132H mutations occur intumors with TP53 mutation, are virtually 
absent in tumors with loss of heterozygosity on 1p and19q and accumulate in distinct 
(gene-expression profiling based) intrinsic molecular subtypes. TheIDH1 mutation type 
does not affect patient survival. Our results were validated on an independentsample 
cohort, indicating that the IDH1 mutation spectrum may aid glioma subtype classifica-
tion.Functional differences between p.R132H and non-p.R132H mutated IDH1 may ex-
plain the segregation in distinct glioma subtypes. 
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Introduction 
The most common type of primary brain tumor (~40%) are gliomas. Based on their his-
tological appearance, gliomas can be divided into three distinct types of tumors accor-
ding to the standard WHO classification (Kleihues and Cavenee 2000): Astrocytic tumors 
(75%), pure oligodendroglial tumors (ODs) and mixed oligoastrocytic tumors (MOAs) 
(25%). Tumors are further classified into grades II, III (anaplastic) and IV (Glioblastomas, 
GBMs) depending on the number of malignant features present. Despite advances in 
neurosurgery, chemotherapy and radiotherapy the prognosis for most glioma patients 
remains dismal (Stupp et al., 2005). 
Recently, a genetic screen identified somatic mutations in the isocitrate dehydro-
genase 1 gene (IDH1; MIM# 147700) in glioblastomas (Parsons et al., 2008). IDH1 ca-
talyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and uses NADP(+) 
as the electron acceptor (Geisbrecht and Gould 1999; Margittai and Banhegyi 2008). 
Additional analysis showed that IDH1 mutations occur at a very high frequency (up to 
80%) in all grade II and III gliomas (astrocytic, oligodendrocytic and oligoastrocytic) and 
secondary GBMs (Balss et al., 2008; Parsons, et al., 2008; Yan et al., 2009; Dubbink et 
al., 2009; Watanabe et al., 2009a; Ichimura et al., 2009; Sanson et al., 2009; Sonoda et 
al., 2009). IDH1 mutations do not occur at significant frequencies in other tumor types, 
with the notable exception of acute myeloid leukemia (AML) (Bleeker et al., 2009; Yan, 
et al., 2009; Mardis et al., 2009). The reported mutations in IDH1 all result in a reduced 
enzymatic activity towards its native substrate, isocitrate (Yan, et al., 2009; Ichimura, et 
al., 2009; Zhao et al., 2009). 
Mutations in the IDH1 gene are heterozygous and virtually always affect only a single 
residue (arginine 132) which is replaced by a histidine in approximately 90% of tumors 
(c.395G>A resulting in p.R132H (Balss, et al., 2008; Ichimura, et al., 2009; Yan, et al., 
2009; Sanson, et al., 2009). However, non-p.R132H mutations in the IDH1 gene (e.g. 
p.R132C) have been reported to accumulate at higher frequencies in histological subty-
pes of glioma (Hartmann et al., 2009), in astrocytomas of Li-Fraumeni patients (Wata-
nabe et al., 2009b) and in patients with AML (Mardis, et al., 2009). Distinct mutations 
within the same gene but affecting the same codon therefore appear to segregate in 
distinct tumor subtypes.  
In this study, we demonstrate that non-p.R132H mutations specifically accumulate 
in distinct histological subtypes of glioma. Because histological classification of gliomas is 
subject to significant interobserver variability (Kros et al., 2007), we also used molecular 
markers (TP53; MIM# 191170), 1p/19q LOH and intrinsic molecular subtypes) to identify 
the glioma subtypes. Our results demonstrate that non-p.R132H mutations indeed se-
gregate in distinct histological, genetic and molecular subtypes of gliomas  
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Materials and methods 
Samples 
Glioma samples were collected from five hospitals in the Netherlands (Erasmus MC, Rot-
terdam; UMCU, Utrecht; NCI and VUMC, Amsterdam; RUNMC, Nijmegen) from patients, 
operated from 1989-2009. Use of patient material was approved by the Institutional Re-
view Board. All samples are listed in Supp. Table S1. Histological diagnoses were made on 
formalin-fixed, paraffin-embedded Haematoxylin & Eosin sections and were reviewed by 
the neuropathologist (J.M.K.). Genomic DNA from snap frozen or formalin fixed, paraffin 
embedded tissue samples was isolated as described (Gravendeel et al., 2009; Dubbink, 
et al., 2009). Of the 496 glioma samples reported in this study, 247 were derived from a 
series of gliomas of all histologies (set A) (Gravendeel, et al., 2009), 54 from a series of 
low grade astrocytomas (set B) (Dubbink, et al., 2009), 24 were derived from samples 
operated in Rotterdam that were included in EORTC 26951 (set C) (van den Bent et al., 
2006) and 171 novel glioma samples (set D). The IDH1 status of 297 samples was des-
cribed previously (Gravendeel, et al., 2009; Dubbink, et al., 2009). IDH1 (NM_005896.2, 
GI:28178824) mutational status of the remaining 199 samples was determined as des-
cribed (Bleeker, et al., 2009), see also Supp. Table S2. 
1p/19q status was determined in 317 samples. 1p19q LOH was determined by flu-
orescent in-situ hybridization (FISH) (Kouwenhoven et al., 2006), inferred from geno-
typing arrays or by microsatellite analysis. Microsatellites were amplified by PCR on 20 
nanogram genomic DNA, using a fluorescently labeled forward primer and a reversed 
primer. Allelic losses were statistically determined as described and scored by two inde-
pendent researchers (French et al., 2005). TP53 (NM_000546.4, GI:187830767) status 
was determined in 169 samples. Primers and cycling conditions to determine the TP53 
mutation status are stated in the Supp. Table S2. 
Statistical analysis 
Comparison between frequencies of different groups was assessed using the Fisher 
exact test. The significance of IDH1 mutation type was assessed by univariate and mul-
tivariate analysis using Cox Regression. Differences between Kaplan-Meyer survival cur-
ves were calculated by the Log-rank (Mantel-Cox) test. Survival time was defined as the 
period from date of surgery to date of death. If date of death was not available, date of 
last follow-up was used. 
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Results and discussion 
Dataset 
We have screened for mutations in IDH1 in a large cohort of 496 glioma samples. In this 
dataset, a total of 246 mutations in the IDH1 gene were identified (49.6%). The IDH1 
mutation frequency for all grades II and III gliomas was high and ranged from 49% in 
anaplastic oligoastrocytic tumors to 79% in low grade oligodendrogliomas (Table 1). The 
frequency of genetic changes in our sample cohort is similar to reported by others (Balss, 
et al., 2008; Ichimura, et al., 2009; Yan, et al., 2009; Hartmann, et al., 2009; Sonoda, et 
al., 2009). The frequency of IDH1 mutations in grade II gliomas (76%, n=110/144) was hi-
gher than in grade III tumors (58%, n=102/177, P<0.001) (see also (Sanson, et al., 2009)). 
More specifically, low grade oligodendrogliomas (79%, n=34/43) and oligoastrocytomas 
(79%, n=22/28) have a higher IDH1 mutation frequency then their corresponding grade 
III tumors (60%, n=64/106 and 49%, n=19/39 respectively P<0.05). A similar difference in 
frequency can also be extracted from at least two external sample cohorts (Hartmann, et 
al., 2009; Watanabe, et al., 2009a). 
The observation of a higher mutation incidence in lower grade tumors has thusfar 
been described for only a few genes (see e.g. (Knowles 2007)). This differential frequen-
cy indicates that low grade tumors can accumulate distinct genetic changes and thus 
represent a different disease entity. Moreover, such differential frequency indicates that 
the IDH1 mutation status can, at least to some extent, serve as a marker for low grade 
gliomas (see also (Jones et al., 2008; Korshunov et al., 2009)). 
Table 1. The frequency of IDH1 (NM_005896.2, GI:28178824) mutations, LOH on 1p and 19q and 
mutations in TP53 (NM_000564.4, 187830767) in different histological. 
n p.R132H p.R132X IDH1 wt 1p/19 LOH no loss nd TP53 mut TP53 wt nd
ODII  
ODIII  
OAII  
OAIII  
AII  
AIII  
GBM
43  
106  
28  
39  
73  
32  
175
34  
63  
21  
15  
48  
15  
31
0  
1  
1  
4  
6  
4  
3
9  
42  
6  
20  
19  
13  
141
21  
57  
6  
3  
2  
1  
10
9  
31  
10  
23  
53  
18  
73
13  
18  
12  
13  
18  
13  
92
0  
7  
1  
8  
29  
12  
27
6  
18  
3  
2  
18  
6  
32
37  
81  
24  
29  
26  
14  
116
total 496 227 19 250 100 217 0 84 85 0
ODII/ODIII: grade II/III oligodendroglioma, OAII/OAIII: grade II/III oligoastrocytoma, AII/AIII: grade 
II/III astrocytoma, GBM: glioblastoma. nd: not determined.  
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Non-p.R132H mutations in IDH1 segregate in distinct glioma subtypes 
The majority of mutations (92.3%) in the IDH1 gene were heterozygous c.395G>A mis-
sense mutations that result in an arginine to histidine substitution on position 132 
(p.R132H). However, 19/246 mutations (7.7%) were non-p.R132H mutations: Single nu-
cleotide changes that result in different amino acid substitutions albeit on the same po-
sition. Similar to reported, c.394C>T (p.R132C) was the second most common mutation 
type in our sample cohort and was identified in nine gliomas. Other non-p.R132H muta-
tions were p.R132S (n=5), p.R132G (n=3), p.R132L (n=1) and p.R132P (n=1). 
When focusing on non-p.R132H IDH1 mutations in our dataset, we observed that 
in classical oligodendrogliomas (combined grades II and III), only one out of the total of 
98 IDH1 mutations (1.0%) was non-p.R132H (Figure 1). A significantly larger proportion 
of non-p.R132H mutations was present in oligoastrocytic tumors (5/41, P<0.01) and in 
astrocytic tumors (10/73, P<0.001). Significance remained within the different tumor 
grades (Figure 1). These results indicate that, although non-p.R132H mutations are rare, 
they are not uniformly distributed across the different histological subtypes of glioma.  
We aimed to confirm the differential distribution of non-p.R132H mutations using 
objective molecular markers. We first screened for combined LOH on 1p and 19q; chro-
mosomal losses that are frequently observed in oligodendrogliomas and relatively rare 
Figure 1. Distribution of non-p.R132H mutations in IDH1 in different histological subtypes of 
glioma. Plotted is the relative frequency of non-p.R132H mutations in IDH1 mutated histological 
subtypes of glioma. Absolute numbers for each subtype is stated in/above individual bars. For 
example, IDH1 mutations are observed in 54 grade II astrocytomas. Of these, six are non-p.R132H. 
As can be seen, non-p.R132H mutations are sporadically observed in oligodendrogliomas and 
more frequent in oligoastrocytomas and astrocytomas. *: P<0.05, **: P<0.01, Fishers’ exact test. 
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in astrocytic tumors (Ohgaki and Kleihues 2009; Bromberg and van den Bent 2009)). The-
se losses are caused by an unbalanced translocation between chromosomes 1 and 19 
[t(1;19)(q10,p10)] (Griffin et al., 2006; Jenkins et al., 2006). In our entire dataset, 1p/19q 
LOH was determined in 317 (63.9%) samples. Of the tumors with combined 1p/19q LOH 
(n=100), a mutation in the IDH1 gene was detected in 75 samples (75%). In these 75 
samples, only one non-p.R132H mutation was identified (1.3%, Figure 2). Conversely, in 
tumors that have retained 1p and/or 19q (n=217), the proportion of non-p.R132H mu-
tations was significantly higher, 13/106 (12.3%, P<0.01). Non-p.R132H mutations there-
fore segregate in tumors that do not show combined 1p/19q LOH. 
We then correlated the type of IDH1 mutation to the TP53 mutation status. TP53 
mutations are frequently observed in astrocytomas and secondary glioblastomas but 
relatively rare in oligodendrogliomas and primary glioblastomas (Collins 2004; Ohgaki 
and Kleihues 2009). In our entire dataset, TP53 mutation status was determined in 169 
samples (34.1 %). Of the tumors with a mutation in TP53 (n=84), a mutation in the IDH1 
gene was detected in 65 samples (77.4%). Non-p.R132H mutations were identified in 
12 of these 65 samples (17.9%, Figure 2). Conversely, in tumors with wt TP53 (n=85), 
the proportion of non-p.R132H mutations was significantly lower (3/54) (5.6%, P<0.05). 
Non-p.R132H mutations therefore accumulate in tumors with a mutation in the TP53 
gene. 
Figure 2. The frequency of non-p.R132H mutations in IDH1 is correlated to distinct genetic chan-
ges in gliomas. Non-p.R132H mutations are more prevalent in gliomas that do not show combined 
LOH on 1p and 19q (left) and in gliomas with a TP53 mutation (right). Absolute numbers for non-
p.R132H mutations/total number of IDH1 mutations are stated in/above the individual bars. *: 
P<0.05, **: P<0.01, Fishers’ exact test. 
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Finally, we determined whether non-p.R132H mutations segregate in intrinsic, gene 
expression based-, molecular subtypes of glioma. In a recent study, we identified seven 
intrinsic glioma subtypes based on gene expression profiles of 276 gliomas of all histolo-
gical subtypes and grades (Gravendeel, et al., 2009). As reported, IDH1 mutations were 
most frequently observed in clusters 9 and 17 (27/40 and 22/32 respectively). When 
focusing on the non-p.R132H mutations (n=8) in this cohort, they were relatively rare in 
cluster 9 (n=1/27, 3.7%) and more frequent in cluster 17 (5/22, 22.7%, P=0.05). Other 
non-R132 samples were identified in clusters that have relatively few IDH1 mutations; 
one in cluster 0 and one in cluster 18 (Gravendeel, et al., 2009). Non-p.R132H mutations 
therefore appear not to be uniformly distributed across intrinsic molecular subtypes of 
glioma.  
Validation of non-p.R132H segregation 
The segregation of non-p.R132H mutations into distinct molecular subtypes of gliomas 
was validated on a recently described independent cohort of glioma samples (Ichimura, 
et al., 2009). In this study, a total of 119 mutations in IDH1 were identified across vari-
ous histological subtypes, nine of which were non-p.R132H. Non-p.R132H mutations are 
clearly more prevalent in IDH1 mutated astrocytomas (7/45) compared to IDH1 muta-
ted oligodendrogliomas (0/35, P<0.05). Furthermore, a significantly higher proportion 
of non-p.R132H mutations was observed in tumors with both IDH1 and TP53 mutation 
(8/65) compared to tumors with wt TP53 (1/52, P<0.05). Finally, all non-p.R132H muta-
tions were identified in tumors that have retained 1p and 19q (9/74 vs. 0/45, P<0.05). 
In summary, non-p.R132H mutations are more prevalent in IDH1 mutated astrocytomas, 
gliomas with TP53 mutation and gliomas that have retained 1p and 19q in this external 
dataset. These data therefore confirm our hypothesis that non-p.R132H mutations in 
IDH1 are more prevalent in distinct subtypes of gliomas.  
IDH1 mutation and patient survival 
In gliomas, the presence of an IDH1 mutation has been associated with prolonged sur-
vival within gliomas of similar malignancy grade (Parsons, et al., 2008; Sanson, et al., 
2009). In our dataset, the IDH1 mutation status was also positively correlated to prolon-
ged survival in the entire dataset (3.3 vs. 0.84 years, P<0.0001) and in glioblastomas (2.0 
vs. 0.72 years, P<0.001). Survival of our sample cohort was similar to population based 
studies (see e.g. (Ohgaki and Kleihues 2005) and www.cbtrus.org). To determine whether 
the IDH1 mutation type affects patient prognosis, we performed survival analysis on 
p.R132H vs. non-p.R132H mutated samples. Univariate analysis indicates that the type 
of IDH1 mutation does not affect patient survival (P=0.74). The IDH1 mutation type also 
does not affect patient survival within histological and/or molecular subtypes of glioma. 
For example, in the molecular glioma subtype that has a relatively large proportion of 
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non-p.R132H mutations (Cluster 17) the median survival between p.R132H (n=17) and 
non-p.R132H (n=5) mutated samples is similar (3.2 and 3.7 years respectively). It should 
be noted that the low numbers of non-p.R132H mutations within defined subtypes may 
obscure relatively small differences. However, multivariate analysis (in which known 
prognostic factors tumor type, grade and age at diagnosis were included), also indicates 
that the type of IDH1 mutation does not affect patient survival (P=0.44). Therefore, the 
IDH1 mutation type does not largely affect patient survival within our sample cohort. 
Non-p.R132H mutations in IDH1 have been reported to accumulate at higher fre-
quencies in distinct histological subtypes of gliomas (Hartmann, et al., 2009) and other 
tumor types (Watanabe, et al., 2009b; Kang et al., 2009; Mardis, et al., 2009). However, 
histological diagnosis of gliomas is subject to significant interobserver variability (Kros, 
et al., 2007). This study therefore provides evidence for the preferential accumulation 
of distinct types of IDH1 mutations not only in histological subtypes of glioma but also 
using molecular markers such as TP53, 1p/19q LOH and intrinsic molecular subtypes. We 
demonstrate that non-p.R132H mutations are relatively frequent in astrocytic tumors, 
tumors with mutation in TP53 and gliomas that do not show combined LOH on 1p and 
19q. Although our results indicate that non-p.R132H mutations occur preferentially in 
tumors with distinct molecular features, it remains to be investigated whether these 
changes are causal for- or associated with- this increased frequency. The sequence in 
mutation events may also influence the type of IDH1 mutation acquired. 
There are two possible explanations for the differential distribution of non-p.R132H 
mutations in glioma subtypes. First, it is possible that (epi)genetic differences between 
tumor types (e.g. differences in DNA repair due to e.g. MGMT (MIM# 156569) promo-
ter methylation) result in the preferential accumulation of distinct mutations (see e.g. 
(Greenman et al., 2007)). For example, MGMT promoter methylation is associated with 
transition type mutations in TP53 in colorectal cancer and in gliomas (Esteller et al., 
2001; Nakamura et al., 2001). Indeed, a higher percentage of oligodendroglial tumors 
show MGMT promoter hypermethylation compared to astrocytic tumors (Wick et al., 
2009; Jeuken et al., 2007; Yang et al., 2009). Differences in the MGMT promoter me-
thylation status between glioma subtypes may therefore explain the differential distri-
bution of non-p.R132H mutations in IDH1. However, the transition/transversion ratio in 
IDH1 (i.e. p.R132H,C/p.R132S,G,L,P) between GBMs, astrocytic tumors (AII/III), oligoas-
trocytic tumors (OAII/III) or oligodendrocytic tumors (ODII/III) is similar (2/32, 5/68, 2/39 
and 1/97 respectively). We also failed to observe a difference in transition/transversion 
ratio in the TP53 gene in the respective histological subgroups (14/12, 26/13, 8/1 and 
5/2). The transition/transversion ratio in the TP53 gene between R132H and non-R132H 
mutated samples is also similar (39/15 and 8/3 respectively). Any possible difference in 
DNA repair between tumor types therefore is not reflected by a difference in the type of 
mutations acquired.  
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A second tentative possibility is that different mutations have different functional 
properties. For example, non-p.R132H mutations may show some residual activity to-
wards isocitrate either in cis (activity of the mutated enzyme itself) or in trans (by in-
fluencing the activity of the remaining wt enzyme (Zhao, et al., 2009)). Alternatively, a 
recent study described that mutated IDH1 is able to convert α-ketoglutarate into 2¬hy-
droxyglutarate (Dang et al., 2009). Interestingly, different IDH1 mutation types showed 
a differential activity towards α-ketoglutarate. Whether this differential activity can ex-
plain the differential distribution of specific types of IDH1 mutations requires further 
detailed analysis. 
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Abstract
Objective: A high percentage of grade II and III gliomas have mutations in the gene en-
coding isocitrate dehydrogenase (IDH1). This mutation is always a heterozygous point 
mutation that affects the amino acid arginine at position 132 and results in loss of its 
native enzymatic activity and gain of alternative enzymatic activity (producing D-2-
hydroxyglutarate). The objective of this study was to investigate the cellular effects of 
R132H mutations in IDH1. 
Methods: Functional consequences of mutations were examined among others using 
fluorescence activated cell sorting, kinome and expression arrays, biochemical assays, 
and intracranial injections on 3 different (glioma) cell lines with stable overexpression 
of IDH1R132H . 
Results: IDH1R132H overexpression in established glioma cell lines in vitro resulted in a 
marked decrease in proliferation, decreased Akt phosphorylation, altered morphology, 
and a more contact-dependent cell migration. The reduced proliferation is related to 
accumulation of D-2-hydroxyglutarate that is produced by IDH1R132H. Mice injected with 
IDH1R132H U87 cells have prolonged survival compared to mice injected with IDH1wt or 
green fluorescent protein–expressing U87 cells. 
Interpretation: Our results demonstrate that IDH1R132H dominantly reduces aggressive-
ness of established glioma cell lines in vitro and in vivo. In addition, the IDH1R132H-IDH1wt 
heterodimer has higher enzymatic activity than the IDH1R132H-IDH1R132H homodimer. Our 
observations in model systems of glioma might lead to a better understanding of the 
biology of IDH1 mutant gliomas, which are typically low grade and often slow growing. 
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Introduction
Gliomas are histologically classified into astrocytic, oligodendroglial, and oligoastrocytic 
tumors. They are further subdivided into low grade (grade II), ana-plastic (grade III), or 
glioblastoma multiforme (grade IV), depending on the presence or absence of malignant 
features. Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1)are very 
common in all grade II and III gliomas, often occurring at frequencies >70%.1,2 The IDH1 
mutation frequency is inversely correlated to tumor grade,3,4 with the lowest frequency 
observed in glioblastoma multiformes.5 IDH1 muta tions are always heterozygous mis-
sense mutations affecting the arginine at position 132. In >90% of the IDH1 mutations in 
gliomas, this arginine is replaced by a histidine (R132H mutation).1,6 
IDH1 mutations are an early event in tumorigene sis; they arise even before TP53 
mutations or loss of 1p and 19q.7 Patients with IDH1 mutations are generally younger, 
and mutations are associated with prolonged survival.3,4,8–11 Mutations in the homolo-
gous IDH2 gene were also identified, although these occur at much lower frequencies in 
gliomas (0–6%).1,12–15 The only other tu mor type in which regular IDH1 and IDH2 mutati-
ons are detected is acute myeloid leukemia (AML).16 
IDH1 catalyses the oxidative decarboxylation of isoci trate into a-ketoglutarate (aKG), 
thereby using nicotinamide adenine dinucleotide phosphate (NADP) as an electron ac-
ceptor.17 The mutated IDH1 enzyme (R132H, IDH1R132H) shows a strongly decreased en-
zymatic activity to ward isocitrate, leading to lower aKG production, thereby increasing 
hypoxia inducible factor 1a levels.15,18,19 In addi tion, IDH1R132H has an altered enzymatic 
activity and uses aKG as a substrate to produce D-2-hydroxyglutarate (D-2 HG).20–22 Alt-
hough it is clear that IDH1R132H has altered en zymatic activity, little is known about how 
the altered enzy matic activity contributes to tumor formation. 
In this study, we have therefore studied the cellular IDH1R132H and functional effects 
of in vitro and in vivo. Our results show that IDH1R132H expression decreases prolifera-
tion rates and alters the morphology and migration pattern of these cells. Although the 
reduced aggressiveness/proliferation found in our study was identified in established 
cell lines that are different from the in vivo growing tumors, our results may help to 
understand the biology of IDH1 mutated gliomas, which are associated with improved 
outcome and are predominantly low grade. 
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Materials and Methods 
IDH1 mutation analysis was performed using forward and reverse primers as described.3 
and IDH1R132H IDH1wt were cloned into pEGFP-C2 bio, which contains a biotin tag befo-
re the green fluorescent protein (GFP) tag. U87, U138, or HEK stable cell lines overex , 
IDH1R132H-GFP pressing IDH1wt-GFP, or GFP were selected for using Geneticin (Gibco, Invi-
trogen, Breda, the Netherlands). Morphology analysis, scratch assay, WST proliferation 
assay,23 fluorescence-activated cell sorting (FACS) cell cycle analysis, and Ki67 staining 
and apoptosis assay were performed as described in the Supporting Information Me-
thods. Cells plated in a 6-well plate were labeled with 1mM bromodeoxyuridine (BrdU) 
(BD Biosciences, Breda, the Netherlands) for 2 hours. Cells were fixed and stained using 
the BrdU In-Situ Detection kit (BD Biosciences) according to the manufacturer’s instruc-
tions. Vis ualization of BrdU-labeled cells was performed using biotin-conju gated anti-
BrdU (1:10) and allophycocyanin-conjugated streptavi din (1:400). Visualization of intra-
cranially injected U87 cells was performed using a mouse antivimentin antibody (DAKO, 
Hever lee, Belgium) and Alexa568-conjugated antimouse antibody (Invi trogen) at 1:300 
and 1:500 dilution, respectively. Sections were counterstained using 4,6-diamidino-2-
phenylindole (DAKO). 
EGFP-C2-bio-IDH1wt or EGFP-C2-bio-IDH1R132H in combination with BirA were tran-
siently expressed by HEK cells, and purified using Streptavidin Dynabeads M-280 (Invi-
trogen) and a Magna-Sep (Invitrogen). Enzyme measurements of iso lated recombinant 
enzymes, of the stable cell lines and in pri mary tumors, were performed as described 
(see also Supporting Information Methods). 
Intracranial injections were performed with the U87 stable cell lines. C.B-17/Icr-
Hantmhsd-Prkdcs SCID mice (Harlan) were stereotactically injected with 1 x 105 tumor 
cells according to a protocol previously described.24 Tumor growth was measured 3x/wk 
in the IVIS 200 system (Xeno gen, Alameda, CA). 
L-2-HG and D-2-HG were measured as described.25 Both L-2-HG and D-2-HG had no 
effect on the pH of the medium in the concentrations used in this study. 
Stable U87 and U138 cell lines were used for mRNA expression analysis on U133 
Plus2 arrays (Affymetrix, Santa Clara, CA). Data were normalized using both the MAS 
5.0 (Affymetrix) and Robust Multi-array Average (RMA)26 algo rithms. Only genes were 
considered that (1) had a >20% dif IDH1R132H-GFP ferent expression level in -expressing 
cells 
IDH1
wt-GFP compared to -expressing cells (in both U87 and U138), (2) had the same 
direction of difference between IDH1R132H-GFP-expressing and GFP-expressing cells, and 
(3) had expression of the gene in both of the 2 compared groups (MAS 5.0 > 30 and RMA 
> 7.0). 
For kinome analysis stable U87 cell lines were used. Pep chip kinomics arrays (Peps-
can, Lelystad, the Netherlands) were hybridized according to the manufacturer’s pro-
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tocol and as described in Parikh et al27 and Sikkema et al28). Pathway analy sis was per-
formed using the Ingenuity Pathways Analysis tool (Ingenuity Systems, Mountain View, 
CA). To compare groups, 2-sided Student t tests were used; otherwise, the statistical test 
used is stated in the text. For more detailed information see also Supporting Information 
Methods. 
Results 
Proliferation 
Three independent cell lines (U87, U138, and HEK) were created that stably overexpress 
IDH1R132H-GFP, IDH1wt-GFP, or GFP. In all 3 cell lines, we observed a IDH1R132H-GFP decreased 
proliferation rate of the  expressing cell lines compared to control (IDH1wt-GFP expressing or 
GFP-expressing) cell lines. The decreased proliferation was observed by WST assays (Fig 
1 and Supporting Information Fig 1) and confirmed by FACS cell cycle analysis (U87). For 
example, FACS analysis on exponentially growing cells showed that the percentages of 
cells in S-phase, G2, or mitosis were lower in IDH1R132H-GFPIDH1wt-GFP-expressing cells than 
in  expressing or GFP-expressing cells (18.3% vs 22.5% and 22.4%, respectively, p < 0.05, 
Mann-Whitney U test). IDH1R132HGFP-expressing cells also had concurrent fewer IDH1wt-GFP
Ki67-positive cells compared to -expressing cells (33.6% and 45.5%) and had a redu-
ced number of BrdU-positive (proliferating) cells in IDH1R132HGFP compared to IDH1wt-GFP 
cells (17.5% vs 19.2%) as determined by FACS analysis. The decreased proliferation was 
not due to differences in apoptosis. Our data therefore demonstrate that established 
cell lines expressing IDH1R132H show lower proliferation rates due to a reduced cell cycle 
activity.
FIGURE 1: Glioma cells expressing mutant IDH1 show reduced proliferation in vitro. WST-1 proli-
feration data of stable U87 cells expressing gamma-fetoprotein (GFP), IDH1wt-GFP, or IDH1R132H-GFP 
are shown. Error bars represent the standard deviation. *p < 0.05, **p < 0.01. wt = wild type.
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To determine whether the reduced proliferation rate of IDH1R132H-GFP-expressing cells 
is also observed in vivo, we performed intracranial injection in mice with our 3 U87 
cell lines. Mice injected with IDH1R132H-GFP-expressing cells had significantly better survival 
(mean 40.3 6 6.9 days) than both the control groups injected with cells expressing either 
IDH1wt-GFP (mean 29 ± 5.8 days, p = 0.0012) or GFP (mean 28.6 ± 5.2 days, p = 0.00058) 
(Fig 2). The difference in survival was obvious, and histological analysis of 1 of the mice 
injected with IDH1R132H-GFP-expressing cells revealed complete absence of tumor at 75 
days, whereas the initial IVIS measurements did detect tumor burden (see Fig 2 and 
Supporting Information Fig 2). Immunohistochemistry showed a reduced GFP staining in 
some of the IDH1R132H-GFP-induced but none of the IDH1wt-GFP-induced tumors, indicating 
that IDH1R132H-GFP expression is, at least partially, lost in the absence of selection pressure 
(Supporting Information Fig 3). Mutant tumor cells were present as indicated by eleva-
ted D-2-HG levels (see below). The reduced proliferation of IDH1R132H-GFP-expressing cells 
in vitro therefore is also apparent in vivo following intracranial injection of IDH1R132H-GFP-
expressing U87 cells.
To further investigate the cellular consequences of the IDH1R132H mutation, we per-
formed a cell migration assay. Cells expressing IDH1R132H-GFP showed a different and more 
FIGURE 2: Glioma cells expres-
sing mutant IDH1 show reduced 
proliferation in vivo. (A) Survival 
curve of 10 mice injected with 
U87-IDH1wt-GFP (black line), 10 
mice injected with U87-IDH1R132H-
GFP (dark gray line), and 10 mice 
injected with U87-GFP (light gray 
line). The mice injected with U87-
IDH1R132H-GFP have a significantly 
longer survival (p < 0.01); 1 mouse 
survived >75 days. (B) IVIS ima-
ging on day 6, 10, and 12 of mice 
injected with U87 cells expressing 
GFP (left), IDH1wt-GFP (middle), 
and IDH1R132H-GFP (right). No-
tice in the right panel that the ini-
tial tumor burden in the rightmost 
mouse decreases. GFP = gamma-
fetoprotein; wt = wild type. [Color 
figure can be viewed in the online 
issue, which is available at www.
annalsofneurology.org.]
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clusterlike (adherent to other cells) migration pattern, ultimately resulting in a tightly 
squeezed line of cells in the middle of the scratched region (Fig 3 and Supporting Infor-
mation Videos 1–3). When counting individual cells (n = 20) in the scratched region, the 
overall motility was significantly less in U87 cells expressing IDH1R132H-GFP than in U87 cells 
expressing IDH1wt-GFP or GFP ( 18.0 ± 2.1µm/h vs 26.3 ± 3.3 and 27.5 ± 3.9 respectively, 
both p < 0.0001). IDH1R132H-GFP-expressing U87 cells also show an altered migration in 
vivo following intracranial injection; clusters of vimentin-positive infiltrative foci were 
approximately twice as frequent in the tumors expressing IDH1R132H-GFP as in those ex-
pressing IDH1wt-GFP in vivo (Fig 4). Such an increase in infiltrative foci in U87 cells has 
also been observed by others.29 The IDH1R132H mutation therefore is not only associated 
with a reduced proliferation rate but also associated with an altered cellular migration 
pattern in an established glioma cell line. Whether these 2 are correlated remains to be 
investigated.
FIGURE 3: Glioma cells expressing mutant IDH1 have an altered migration pattern. Scratch assay 
results of U87 cells overexpressing gamma-fetoprotein (GFP), IDH1wt-GFP, or IDH1R132H-GFP are shown. 
The U87 cells overexpressing IDH1R132H-GFP show a reducedmotility and cluster tightly together on the 
scratched surface area (see also Supporting Information Videos 1–3). wt = wild type.
110
Chapter 6
Altered Enzymatic Activity of IDH1R132H-GFP Is Increased in the Presence of 
IDH1wt-GFP 
Thus far, all reported enzymatic experiments have been performed using extracts of cells 
overexpressing wild-type or mutant IDH1.15,18 Similar to the findings reported by these 
groups, our cell lines stably expressing IDH1R132HGFP also show reduced enzymatic activity 
toward isocitrate and increased activity toward αKG compared to IDH1wt-GFP (Fig 5 and 
Supporting Information Figs 4 and 5). Patient-derived tumors with IDH1 mutations (n = 
5, all R132H) also showed reduced enzymatic activity toward isocitrate (p = 0.037) (see 
Supporting Information Figs 5 and 6).
Subsequently we sought to examine whether the altered enzymatic activity of 
IDH1R132H could be recapitulated in a purified protein system with our constructs. For 
these experiments, we generated constructs in which a biotag was added to the N-ter-
minal end of the protein. Biotagged constructs could then be purified following bioti-
nylation and streptavidin-conjugated magnetic beads. As reported using extracts of cell 
lines, IDH1bio-wt-GFP had enzymatic activity toward isocitrate and not toward aKG and 
vice versa for IDH1bio-R132H-GFP. The activity was dose dependent for both isocitrate 
and enzyme concentration (not shown). A 1:1 mixture of IDH1wt-GFP and IDH1R132H-GFP 
showed intermediate activity toward isocitrate (see Fig 5). Surprisingly, in this purified 
protein system,
the IDH1bio-R132H-GFP activity was more active toward aKG in the presence of IDH1bio-
wt-GFP enzyme. More αKG is converted in these mixture experiments, although they 
contained only half of the IDH1bio-R132H-GFP of the nonmixture experiments (all experiments 
contained equimolar amounts of enzyme). These results indicate that the presence of 
IDH1bio-wt-GFP increases the enzymatic activity of IDH1bio-R132H-GFP toward αKG.
2-Hydroxyglutarate Reduces Proliferation
Our next experiments were aimed at determining whether the reduced proliferation 
rate of IDH1R132H-GFP-expressing cells is a consequence of the D-2-HG produced by the mu-
tant enzyme. In our U87 cell lines, D-2-HG concentrations are strongly increased, both in 
cell pellets (68µmol/mg protein) and in the medium (55µmol/l) (Supporting Information
Fig 7). L-2-HG levels were not affected by IDH1R132H-GFP expression. Similar increa-
ses were observed in cell extracts of intracranially injected tumors (26.9µmol/l vs 
1.35µmol/l, p = 0.014, see also Supporting Information Fig 7).
The concentrations of D-2-HG measured in pellets and media were used to spike 
this metabolite into the medium of U87 cells expressing GFP. Both D-2-HG and L-2-HG 
reduced the proliferation of these cells in a dose-dependent way as measured by FACS 
cell cycle analysis (Fig 6). The percentage of cells in G2-SM phase was reduced from 
20.1% to 15.2% and 7.7% (p = 0.018 and p = 0.037, respectively) by the addition of 3 
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and 6mmol/l D-2-HG. This was confirmed by WST analysis using 30mmol/l D-2-HG (46% 
decrease in growth compared to U87 without D-2-HG, p < 0.001). A reduction in cellular 
proliferation was also observed when performing a BrdU proliferation assay; the number 
of BrdU-positive U87 cells was reduced from 26.6% to 23.4% in the presence of 1.2mM 
D-2-HG. Similar percentages of BrdU-positive U87 cells have been observed by others.30 
These results indicate that the reduced proliferation rate observed in U87 cells in vitro is 
at least partly mediated by the accumulation of D-2-HG.
The decrease in proliferation was not accompanied by an increase in apoptosis as 
determined by FACS analysis; the number of annexin V-positive cells in U87 cells was not 
increased in the presence of D-2-HG (5.5%, 5.2%, and 5.9% for 0.12, 0.6, and 1.2mM D-2-
HG, respectively) compared to control U87 cells (6.9%). These results are in line with our 
observation that IDH1R132H-GFP-expressing cells do not show an increase in apoptosis 
(see above) despite having elevated levels of D-2-HG.
FIGURE 4: Glioma cells expres-
sing mutant IDH1 have an altered 
migration pattern in vivo. Intra-
cranially injected U87 cell tumors 
expressing IDH1R132H-GFP (bottom 
panel) are characterized by the 
presence of infiltrative foci (arro-
wheads). Such foci were observed 
much less frequently in tumors 
expressing IDH1wt-GFP (top panel). 
Red = vimentin; blue = 4,6-dia-
midino-2-phenylindole; wt = wild 
type; GFP = gammafetoprotein.
[Color figure can be viewed in the 
online issue, which is available at 
www.annalsofneurology.org.]
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Downstream Pathway Analysis
It is unknown which oncogenic pathways are affected by IDH1R132H and D-2-HG. We there-
fore performed expression profiling to further analyze the downstream pathways. Only 
7 genes (Table) were identified that show an IDH1R132H-GFP-associated differential ex-
pression of >20% in both U87 and U138 cells. Ingenuity pathway analysis indicated that 
these genes are not significantly linked to any canonical pathway, but can be linked to a 
single network involved in tumor morphology, cellular development, and cellular growth 
and proliferation (Supporting Information Fig 8). However, the number of differentially 
expressed genes is too few to significantly address downstream pathway activation.
Kinome profiling on our 3 U87 cell lines was then performed to further examine 
the pathways affected by IDH1R132H-GFP. Seven kinases were significantly differentially ac-
tivated between IDH1R132H-GFP-expressing cells and both IDH1wt-GFP-expressing and GFP-ex-
pressing cells (p < 0.05) (see Table). One of the most differentially activated kinases was 
AKT1, showing less activity in IDH1R132H-GFP-expressing cells. Immunocytochemistry 
using phospho-AKT specific antibodies confirmed the reduced AKT1 activity in IDH1R132H-
GFP-expressing cells (Supporting Information Fig 9). As AKT1 activation is positively cor-
related with cell proliferation, kinome profiling confirms the reduced proliferation ob-
served in IDH1R132H-GFP-expressing U87 cells.
FIGURE 5: Wild-type (wt)–mutant IDH1 di-
mers are enzymatically more active toward 
a-ketoglutarate than mutant IDH1. (A) Enzy-
matic activity of purified enzyme as measured 
by nicotinamide adenine dinucleotide phosp-
hate hydrogen (NADPH) production (expressed 
by OD340) in the presence of isocitrate and 
NADP; IDH1wt-GFP (blue line) and IDH1R132H-GFP 
(red line) or a 1:1 mixture of both (purple line). 
Gamma-fetoprotein (GFP) (green line) is used 
as a control. (B) Enzymatic activity as measured 
by NADPH use in the presence of a-ketogluta-
rate of IDH1wt-GFP (blue line), IDH1R132H-GFP (red 
line), a 1:1 mixture of IDH1wt-GFP and IDH1R132H-
GFP (purple line), and GFP (green line). Error bars 
represent the standard error of the mean.
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Discussion
To our knowledge, we are the first to describe the cellular effects of IDH1R132H-GFP ex-
pression in established cell lines. Our data strongly indicate that IDH1R132HGFP reduces the 
proliferation rate of various cell lines, as is demonstrated by WST assays, FACS cell cycle 
analysis, and Ki67 staining. These results were supported morphologically (visualized by 
a reduced population of elongated, actively dividing, cells) and by kinome profiling (as 
indicated by a reduced AKT activation). The reduced proliferation in vitro was confirmed 
in vivo following intracranial injection of IDH1R132H-GFP-expressing cells.
It is possible that the reduced proliferation rate in established glioma cell lines ex-
plains why only 1 tumor cell line expressing IDH1R132H has been reported,31,32 although 
xenografts of glioblastomas with IDH1 mutations have been described.5 In fact, we exa-
mined 13 primary cell cultures on serum propagated from IDH1 mutated gliomas. No 
primary tumor cell culture bearing the IDH1 mutation could be established from any of 
these gliomas. A reduced presence of the IDH1 mutation was already visible in the first 
passage of these cells as a reduced peak on sequence chromatograms (R.B. and M.L., 
unpublished observations). However, a correlation between difficulties of culturing IDH1 
mutated gliomas and reduced proliferation in established cell lines should be treated 
with caution, as many other factors might contribute to poor growth of (lower grade) 
gliomas in vitro.
FIGURE 6: D-2-hydroxyglutarate 
(D-2HG) reduces proliferation of 
glioma cells. Dose-dependent ef-
fects of D-2-hydroxyglutarate on 
the cell cycle of U87 cells expres-
sing gammafetoprotein (GFP) as 
measured by fluorescence-acti-
vated cell sorting are shown. PI = 
propidium iodide.
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It is interesting that the effects of IDH1R132H were so apparent although the mutation 
was introduced into highly malignant glioma cell lines. This demonstrates the dominant 
nature of mutant IDH1 in established cell lines. If mutant IDH1 is also causal for reduced 
proliferation in gliomas, it might explain why IDH1R132H is inversely correlated with tumor 
grade3,4 and why IDH1R132H is an independent favorable prognostic marker in glioma 
patients1,4 However, it is possible that the effect of IDH1R132H expression observed in this 
study is associated with its expression in highly malignant cell lines that have a distinct 
set of genetic changes (see, eg, Clark et al33). Therefore, the effect of IDH1R132H expression 
on nonmalignant cell types, low-grade gliomas, and/or cancer stem cells remains to be 
determined. 
Our results appear contradictory, with a presumed oncogenic role of IDH1R132H 
and D-2-HG as an oncometabolite.20,22,34 However, our results may be explained if IDH1 
mutation only has a favorable role in tumor initiation, but is unfavorable for tumor pro-
gression. Indeed, IDH1R132H is the first hit,7 does not accumulate secondary to tumor 
formation, and anecdotally is lost in part of the tumor after malignant progression.35 
TABLE I: Differentially Expressed Genes and Activated Kinases in Mutant IDH1-Expressing Cell Lines
Gene Expression in Mutant Fold Change
BTG3 Overexpressed 1.672
CCNG1 Overexpressed 1.514
CD99 Overexpressed 1.727
SERPINE1 Overexpressed 2.865
HNRPDL Underexpressed 0.714
PPP1CB Underexpressed 0.703
TMED7 Underexpressed 0.540
Kinase Activation in Mutant Fold Change
Activin A receptor, type 1 Higher 2.15
MARK Higher 1.62
AKT1 Lower 0.82
MAPK4 Lower 0.66
Ribosomal protein S6 alpha 4 Lower 0.64
SHP2 Lower <<
TAO kinase 2 Lower 0.66
Gene = Differentially expressed genes in IDH1R132H-GFP-expressing cell lines (U87 and U138) compa-
red to IDH1wt-GFP expressing cell lines. Kinase = Differentially activated kinases in IDH1R132H-GFP-
expressing U87 cell lines compared to IDH1wt-GFP-expressing and GFP-expressing U87 cell lines. < = 
no expression detectable anymore. wt = wild type; GFP = gamma-fetoprotein.
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However, our results may also be explained if IDH1R132H does not contribute to tumor 
formation, or if effects observed in this study are specific to the cell lines used. A causal 
role has not yet been established. Alternative functions of IDH1R132H can also explain a 
possible role in oncogenesis.
A similar discussion can be held on D-2-HG as an oncometabolite. IDH1 or IDH2 
mutations result in an increase in D-2-HG in serum and tumors of AML21,22 and glio-
ma20 patients (see also Supporting Information Fig 7), whereas we demonstrate that 
D-2-HG reduces the proliferation rate of glioma cells. These results appear contradictory 
to a presumed role of D-2-HG as an oncometabolite, but it is possible that D-2-HG only 
plays a role in tumor initiation. However, accumulation of D-2-HG is also not associated 
with brain tumor formation (whereas L-2-HG is),36 which might suggest D-2-HG has no 
tumor-initiating capacities and is solely an inevitable byproduct. If so, mutated IDH1 or 
IDH2 has oncogenic properties not associated with D-2-HG. It has been reported that 
the IDH1 and IDH2 mutation spectra differ across the various diseases (glioma, AML and 
D-2-HG aciduria).6,13,36,37 It is tempting to speculate that these oncogenic properties 
vary across the different IDH1 and IDH2 mutations.
To further elucidate a possible function of mutant IDH1, we have recently performed 
methylation profiling (Infinium Human methylation 27 arrays [Illumina, San Diego, CA]) 
on a panel of 68 anaplastic oligodendrogliomas and oligoastrocytomas (P.J.F., manus-
cript in preparation). In this study, the CpG island methylator phenotype (CIMP) was 
highly correlated with the presence of IDH1 mutation. These data are in line with the 
recently suggested hypothesis that IDH1 induces promoter methylation.38 However, not 
all IDH1 mutated tumors are CIMP positive, nor is the effector gene TET2 differentially 
expressed between IDH1wt-GFP-expressing and IDH1R132H-GFP-expressing U87 and U138 
cells. It therefore remains to be determined whether IDH1 mutations also result in pro-
moter methylation in glioma.
Our purified enzyme system allowed us to examine the properties of wild-type–mu-
tant enzyme mixtures. Interestingly, our results show that the 1:1 mixture of IDH1bio-wt-
GFP-expressing and IDH1bio-R132H-GFP-expressing cells has the highest reductive enzymatic 
activity.
The altered enzymatic activity therefore is stimulated by the presence of wild-type 
enzyme. To our knowledge, this is the first paper to examine the altered enzymatic ac-
tivity of IDH1R132H-GFP in a purified protein system. Others have studied and reported on 
IDH1 mutated enzymes from cell lysates that also contain endogenous IDH122 or have 
not tested the enzymatic activity to ward aKG of the combination of IDH1 mutant and 
wild-type enzyme.19,21 The increased alternative enzyme activity could be explained by 
the fact that IDH1 func tions as a dimer. In this model, the aKG produced by wild-type 
IDH1 in wild-type–mutant heterodimers improves substrate availability for mutant IDH1. 
Alter natively, heterodimers confer a more active conforma tional state of mutant IDH1. 
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IDH1 can only function as a dimer,1 and therefore it is possible that wt-IDH1 enzymes in 
wt-mutant IDH1 heterodimers may induce a different conformational state than IDH1 
mutant homodimers. Such an altered state can result in increased activity of the mutant 
enzyme. The increased alternative enzyme activity of the wild-type–mutant combina-
tion is in line with the observation that virtu ally all IDH1 mutations are heterozygous. 
In conclusion, IDH1R132H-GFP-expressing cell lines show a reduced proliferation rate in 
vitro and better sur vival in vivo. Our results obtained in model systems of gli oma may 
help explain the biology of IDH1 mutated glio mas, which are typically low grade and 
slow growing. 
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Abstract 
A common and histologically well defined subtype of glioma are the oligodendroglial 
brain tumors. Approximately 70% of all oligodendrogliomas have a combined loss of 
the entire 1p and 19q chromosomal arms. This remarkably high frequency suggests that 
the remaining arms harbor yet to be identified tumor suppressor genes. Identification 
of these causal genetic changes in oligodendrogliomas is important because they form 
direct targets for treatment. In this study we therefore performed targeted resequencing 
of all exons, microRNAs, splice sites and promoter regions residing on 1p and 19q on 7 
oligodendrogliomas and 4 matched controls. Only one missense mutation was identified 
in a single sample in the ARHGEF16 gene. This mutation lies within-and disrupts the con-
served PDZ binding domain. No similar ARHGEF16 mutations or deletions were found 
in a larger set of oligodendrogliomas. The absence of common somatic changes within 
genes located on 1p and 19q in three out of four samples indicates that no additional 
‘‘second hit’’ is required to drive oncogenic transformation on either chromosomal arm. 
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Introduction 
A common and histologically well defined subtype of glioma are the oligodendroglial 
brain tumors. Oligodendrogliomas differ from the other glioma subtypes in clinical beha-
vior with respect to overall prognosis (median survival 3 years versus less than one year) 
and a relatively better and longer lived response to chemotherapy and radiotherapy [1–
3]. Oligodendrogliomas have clearly distinct gene expression profiles [4–6] and are also 
cytogenetically distinct: approximately 70% of all oligodendrogli omas have a combined 
loss of the entire short arm of chromosome 1 (1p) and loss of the entire long arm of 
chromosome 19 (19q) [1,3–5,7]. Loss of these chromosomal arms in oligodendrogliomas 
is highly correlated with chemosensitivity; approximately 80–90% of oligodendroglial tu-
mors with LOH (loss of heterozygosity) on 1p and 19q respond to chemotherapy [1,2,8]. 
Conversely only 25– 30% of tumors that have retained the short arm of chromosome 
1p are sensitive to chemotherapy. In summary, oligdendrogliomas are a clinically, histo-
logically, cytogenetically and molecularly distinct and well defined subgroup of glioma. 
In spite of these clearly distinct clinical, histological and molecular features, little is 
known on the genetic changes that drive these tumors. Thusfar, IDH1/IDH2 (70%) and, 
to a much lesser extent, TP53 (15–25%) and PIK3CA (10–15%) are the only genes that 
are mutated at significant frequency in this tumor type [9–15]. The remarkably high 
frequency of LOH of 1p and 19q suggests the remaining arms harbor yet to be identified 
tumor suppressor genes (Knudson two-hit hypothesis [16]). Identification of the cau-
sal genetic changes is important because they form direct targets for treatment: Tumor 
growth depends on these acquired somatic-changes both in oncogenes (‘‘oncogene ad-
diction’’ [17]) and in tumor suppressor genes [18,19]. In this study we therefore aimed 
to identify genetic changes in all exons, microRNAs, splice sites and promoter regions 
on 1p or 19q using array capture and Next Generation Sequencing. Experiments were 
performed on 7 oligodendrogliomas and 4 had matched control DNA samples. 
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Materials and Methods 
Glioma samples were collected from the Erasmus MC tumor archive. Samples were col-
lected immediately after surgical resection, snap frozen, and stored at 280uC. The use of 
patient material was approved of by the Institutional Review Board of the Erasmus MC, 
Rotterdam, the Netherlands (nr MEC 221.520/2002/262; date of approval July 22, 2003, 
and MEC-2005-057, date of approval February 14, 2005). For this use, patients gave writ-
ten informed consent according to institutional and national guidelines. 
All oligodendrogliomas used (n = 7) had proven loss of 1p and 19q as assessed by 
SNP 6.0 or 250 k NspI arrays (both Affymetrix, Santa Clara, USA) [7] and highly similar 
RNA expression profiles (i.e. belong to the same molecular subgroup) [6]. Control DNA 
was available in 4/7 cases. The candidate variations of 4 samples were used for valida-
tion experiments. By using 4 samples we have a 76.0% chance of identifying each muta-
tion with a frequency of 30%. DNA was amplified using a Repli-G midi kit (Qiagen, Venlo, 
the Netherlands) to ensure sufficient DNA amounts. Patient characteristics are listed in 
table 1. 
Capture arrays (Nimblegen, Roche NimbleGen, Inc., Waldk raiburg, Germany) were 
designed to enrich for all exons, miRNAs, splice sites (defined as 10 bp up-or down-
stream of a coding exon) and promoter regions (defined as 100 bp upstream of a trans-
cript) of transcripts present in Refseq, Ensembl or Vega based on the NCBI36/hg18 build. 
Two capture arrays were designed covering around 5 million bp of sequence each. We 
were able to design capture probes for 96.0% and 94.4% of all regions on chr 1 and chr 
19 respectively, remaining sequences contained non unique sequences (.5 fold presence 
in the human genome). Amplified DNA samples were fragmented by sonication, end re-
paired and ligated to paired end adaptors. Samples were size selected (300 bp), enriched 
for 1p and 19q by array capture, PCR amplified and 76 bp paired end sequenced using 
the Illumina GA2x sequencer. The Illumine Casava pipeline was used for base calling and 
quality control. 
The CLC Bio Genomics Workbench (Aarhus, Denmark) was used to align sequence 
reads against the reference genome. All the experiments were successful except for one 
of the two capture arrays of sample 229, which was omitted from the analysis. We de-
fined reads subject for mutational analysis as being covered at least 7 times in the tu-
mor sample and at least 8 times in the matching control sample. This coverage was set 
deliberately low (often $30 fold coverage is used) and was aimed to include as many 
evaluable targeted regions as possible. 
Single Nucleotide Variants (SNVs) and Deletion or Insertion Variants (DIVs) were 
detected by the CLC Bio Genomic Workbench and filtered using the following criteria 
(coverage of at least 7 (tumor) or 8 (ctr), variant frequency at least 70% (tumor) or 30% 
(controls). The difference in variant frequency between tumors and normals is because 
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only homozygous changes are expected in the tumor (because of the 1p19q LOH). To 
allow for tumor heterogeneity (presence of non-neoplastic tissue) and stochastic effects 
(allele specific sequencing) these percentages were set lower than 100% and 50%. 
Results 
The mean total number of matched bp sequenced per sample was 2.89 billion (1.17 bil-
lion in sample 229). Of these, 73.5% was on our targeted regions (range 70.4–84.8%, one 
outlier at 41.3%) confirming capture efficiency. The coverage of our targeted regions was 
at least 7 in 96.5% of our target regions (range 87.6– 98.9) (see also figure 1). Coverage 
of genes suggested to be involved in (oligodendro-) glioma genesis CAMTA1 [20], EMP3 
[21], CHD5 [22], DIRAS3 [23] and PLA2G4C [24] is listed in table 2. 
We first calculated the tumor percentage of all samples. The tumor content can be 
estimated by the observed B allele frequency of SNPs using tumor samples only. For 
example, in case of 50% tumor, the observed B allele frequency would amount to 66.7% 
(in case of LOH in the tumor). In our sample cohort, the observed B allele frequency was 
91.2–97.3% (except for sample 11 with an observed frequency of 85.0%), corresponding 
to 90.3–97.2% tumor (82.4% for sample 11). A tumor content $82.4% indicates that a 
mutant allele frequency of 70% (corresponding to a tumor percentage of 82.4%) is a 
suitable value as detection cutoff for the mutant allele frequency. 
Table 1. Patient characteristics of all tumor samples. 
Sample Gender Diagnosis Age KPS Surgery RT CT Alive Surv (years)
8 F OD III 44 100 PR yes no Dead 9.82
11 M OD III 38 CR yes no Dead 8.92
13 M OD III 33 90 PR Dead 8.59
21 M OD III 31 100 PR yes no Dead 6.81
23 F OD III 44 90 CR yes no Dead 8.12
229 M OA III 35 90 CR yes Adj PCV Alive 6.8
538 F OD II 44 80 SB Alive 3.27
OD = oligodendroglioma, OA = oligoastrocytoma, KPS = Karnofsky performance score, PCV = pro-
carbazine, lomustine, vincristine.
F = female, M= male, OD = oligodendroglioma, OA = oligoastrocytoma, grades II or III. Age = age at 
diagnosis. KPS = Karnofsky performance score, PCV =
procarbazine, lomustine, vincristine. Surgery types: PR = partial resection, CR = complete resec-
tion, SB = stereotactic biopsy. RT = radiotherapy, CT = Chemotherapy.
126
Chapter 7
We then prioritized all changes identified based on their associated function into: 
tier 1 (coding exons, splice sites and miRNAs), tier 2 (promoters and UTRs), tier 3 (intro-
nic regions) and tier 4 (SNPs and personal SNPs). In tiers 1, 2, 3 and 4 we identified 431, 
1380, 16293 and 72466 SNVs and DIVs respectively. A high number of all variants pre-
sent in tier 4 were not present in dbSNP130, and are likely to reflect personal SNPs and 
sequencing artefacts (see also table 3). We then performed direct sequencing on all tier 
1 candidates and all candidates within promoter regions (part of tier 2). 505 of the 514 
sequence reactions were successful; only 2/9 unsuccessful candidates were predicted to 
result in a change in the primary protein sequence (both missense mutations). 
Of the 514 candidate variants 77% (n = 394) were not confirmed on tumor DNA 
using direct sequencing (false positive). Such variants likely represent amplification ar-
tefacts (due to e.g. whole genome amplification or the post capture PCR amplification) 
and/or sequencing artefacts (e.g. sequencing errors). A further 21% (n = 110) could be 
confirmed in the tumor samples, but the variant was also present in the matched con-
trol DNA. These variants may represent selective allele amplification and sequencing. In 
summary, of the 514 candidates subject to direct sequencing, one variant was validated. 
This variant is a missense mutation (c.2125 G.A) (figure 2a) and affects the last amino 
acid (p.V709M) of ARHGEF16 (RefSeq: NM_014448.3) in sample 8. It should be noted 
that the absence of trace wt sequence in the chromatogram confirms the high tumor 
percentage in this sample. The base is highly conserved (GERP conservation score 3.35 
[25]. This amino acid is located within a PDZ-binding domain (ETDV, a protein-protein 
interaction domain). However, it remains to be determined whether the identified muta-
tion affects its RhoA guanine exchange function and oncogenic transformation potential 
[26]. 
Figure 1. Coverage plot of all samples. Depicted is the percentage of targeted bases (y-axis) that is 
covered at least n times (x-axis) per sample. 
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None of the other 6 samples contained changes in the coding sequence of ARHGEF16. 
In addition, we failed to identify mutations in the last exon of ARHGEF16 in an additio-
nal 32 samples from the same molecular cluster [6] using direct sequencing. No small 
homozygous deletions were identified on SNP 6.0 and 250 k Nsp arrays from 23 oligo-
dendrogliomas [7]. The ARHGEF16 promoter does show hypermethylation on Infinium 
Methylation arrays (Illumina, San Diego, USA), on 68 anaplastic oligodendrogliomas and 
oligoastrocytomas; PF, manu script in prep) and is correlated with loss of 1p and 19q 
(p = 0.035, Fisher exact test). Data are listed in table 4. In addition, tumors with hyper-
methylated ARHGEF16 promoter have a better survival (5.62 years versus 1.31 years; 
p,0.0001) (figure 2b). Promoter methylation of ARHGEF16 may therefore be involved in 
the formation of gliomas with loss of 1p and 19q. 
Table 2. Per base coverage of known candidate genes in oligodendrogliomas located on 1p or 19q.
Sample CAMTA CHD5 DIRAS3 PLA2G4C EMP3
8 cov 200.1 264.4 107.2 32.3 57.0
min 0 5 26 2 15
max 896 1198 186 87 131
% covered 96.2 99.6 100 93.1 100
11 cov 58.6 20.2 127.0 79.0 90.2
min 0 0 12 7 33
max 275 107 231 214 183
% covered 93.5 82.1 100 100 100
13 cov 184.6 135.8 98.5 183.8 343.1
min 0 0 14 24 126
max 562 677 178 447 625
% covered 98.2 94.0 100 100 100
21 cov 163.8 77.7 208.1 202.8 281.3
min 0 2 24 50 95
max 527 329 360 449 599
% covered 96.8 98.9 100 100 100
23 cov 178.8 69.0 245.8 189.4 202.3
min 0 0 35 21 70
max 531 353 468 487 374
% covered 95.9 89.9 100 100 100
Min/Max: lowest/highest coverage, % covered: the percentage of bases sequenced at least 7 
times (the cutoff used for our analysis).
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Discussion 
We have systematically sequenced all exons, miRNAs, splice sites and promoter regions 
on 1p and 19q. Of the 514 candidate variants in coding exons, miRNAs, splice sites and 
promoter regions, only one was validated: a missense mutation in ARHGEF16 affecting 
the PDZ-binding domain. ARHGEF16 lies on 1p36 a region that is commonly deleted in 
gliomas [20,22,27]. However, no other genetic changes were detected in the ARHGEF16 
gene in a panel of 32 additional oligodendrogliomas, though the promoter is frequently 
hypermethylated. Future experiments should determine whether this specific mutation 
contributes to the pathogenesis of the disease. 
In our sample cohort, only one somatic mutation in a single sample was identified among 
the ,10
7 
bases of sequence evaluated. The overall mutation rate in oligodendrogliomas 
therefore is at least an order of magnitude lower than reported for many other cancer 
types including glioblastomas [12,28,29]. Recent reports however, have highlighted tu-
mor types that also have a very low somatic mutation rate [30,31]. 
One important observation by our study is the fact that in 3 out of the four samples 
examined no genomic second hit was found in any of the screened regions. Our data 
therefore indicate that no additional ‘‘second hit’’ is required on these chromosomal 
arms to drive oncogenic transformation. It is possible that a second hit is present on 
the remaining alleles but has escaped detection (e.g. due to a skewed distribution in se-
quencing of the non-neoplastic alleles derived from ‘‘contaminating’’ normal tissue) or is 
located in regions not captured or covered by our capture array. Alternatively, promoter 
methylation and/or haploinsufficiency of one or more genes could drive oncogenesis 
in oligodendrogliomas with loss of 1p and 19q. In line with this hypothesis is the high 
frequency of IDH1 mutations in oligodendrogliomas with 1p and 19q LOH (see e.g. [32]) 
and the observation that IDH1 mutations induce chromatin remodeling and promoter 
hypermethylation [33,34]. IDH1 mutations are associated with the CpG island hyperme-
thylation phenotype (MvdB and PF, submitted), and promoter hypermethylation in can-
cer often occurs in the promoter regions of tumor suppressor genes [35,36]. Promoter 
hypermethylation of tumor suppressor genes in combination with somatic mutations in 
a limited number of genes therefore may drive oncogenesis in oligodendrogliomas with 
1p and 19q LOH.
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Figure 2. ARHGEF16 (RefSeq: NM_014448.3) mutation and promoter methylation. A; Upper lane: 
part of the sequence of ARHGEF16 with the missense mutation (2125G-.A) in tumor sample 8. Lo-
wer lane: sequence of the same region of ARHGEF16 in the matching control DNA. B; Kaplan Meier 
survival curve of oligodendrogliomas (n = 39) and oligoastrocytomas (n = 11) with unmethylated 
ARHGEF16 (, median) (black line) or methylated ARHGEF16 (. median) (grey line). ** = p,0.01.
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Concluding remarks and future directions
In this thesis novel methods to screen for translocations are described and one candi-
date gene, the CASPR2 gene, was functionally analyzed and was found to be a tumor 
suppressor gene in glioma. We found that a subgroup of the recently discovered R132 
mutations in IDH1 (the non-p.R132H mutations) are segregated in distinct molecular 
subgroups. The functional analysis of the R132H mutation in the IDH1 gene showed that 
the expression of this mutated gene in glioma cell lines decreases proliferation in vitro 
and also in vivo. Our next generation sequencing mutation screen in oligodendrogliomas 
with loss of 1p and 19q showed no additional mutations above detection levels in genes 
on the remaining alleles. 
The last decade, mRNA expression- and SNP arrays have produced large amounts of data 
that have resulted in a much greater insight in glioma genomics and genetics (see also 
chapter 3 of this thesis). More recently, large scale sequencing efforts have revealed an 
even greater insight into the biology of gliomas (Parsons, Science 2008, Bettegowda, 
Science 2011). Caveats of this deep sequencing techniques are that allele specific se-
quencing, regions poorly covered and the mutation detection algorithm may all result 
in false negative mutation calls, as was the case in our mutation screen (see chapter 7). 
The rapid development of novel sequencing techniques will lead to even more ge-
netic data in the next decade. Therefore, it can be expected that virtually all genetic 
changes in all glioma subtypes will be identified in the near future. 
As the knowledge of all regions of the DNA expands (e.g. think about the discovery 
of miRNAs), also the value of the changes in what is now called “junk” DNA will be clari-
fied (Pink, RNA 2011). In spite of the importance of whole genome sequencing, it has to 
be taken into account that genetic alterations are at the beginning of mRNA and protein 
level changes. Epigenetic alterations (e.g. methylation (Noushmehr, Cancer Cell 2010)), 
and post transcriptional and translational modifications of proteins can have their ef-
fects on cell behavior and in that way can contribute to cancer formation.   
Cancer is thought of as a genetic disease and before normal cells become malignant 
tumor cells they need genetic alterations in genes in several pathways, like pathways 
involved in growth and apoptosis. Logically, the genetic alterations in these genes and 
their effects are good targets for treatment. For example, in leukemia this resulted in the 
use of imatinib, which is a specific tyrosine kinase inhibitor that works on leukemic cells 
that express the BCR-ABL fusion protein (Buchdunger, Cancer Res 1996).  
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One of the emerging concepts that came out of genome sequencing efforts is that not all 
genetic changes in gliomas (or other tumors) are causal for the disease. These  so-called 
“passenger” mutations can arise during cell division and are then found throughout the 
tumor due to clonal expansion (Greenman, Nature 2007). In fact, the majority of somatic 
mutations in cancer may be such “passenger” mutations (Greenman, Nature 2007). Dis-
tinguishing the causal “driver” mutations from such “passenger” mutations is therefore 
required and will be a major focus of cancer research in the near future.
One way to distinguish driver from passenger mutations is by frequency analysis: 
causal genetic changes are thought to occur at a higher incidence than predicted by 
chance. This strategy is used in the studies described in chapter 3, 4, 5 and 7 of this 
thesis. Specifically, in chapter 5 we show that frequency analysis within different glioma 
subtypes (molecular and histological) can also give insight into probable functional dif-
ferences of the distinct mutation types within a gene. However, few genetic changes are 
recurrent events (so-called “mountains” in the genomic landscape of tumors (Wood, 
Science 2007)); only a handful of genes are mutated at frequencies >10%  not only in 
gliomas (TCGA, Nature 2008; Parsons, Science 2008; Greenman, Nature 2007) but also in 
many other cancer types (Sjoblom, Science 2006; Parsons, Science 2010). These studies 
show that many more genes are mutated at low frequencies (so-called “hills”). In chap-
ter 4 we show that such infrequent candidates can contribute to tumor formation and/
or progression and therefore can give insight into the process of tumorigenesis. 
At this moment the functional analysis is too low throughput for all future genetic 
alterations to be analyzed.  The technical revolution that has already taken place in the 
field of the detection of genetic alterations will have to spread to the functional analysis 
of these genes. This high throughput functional testing will be the next necessary step in 
the process to distinguish the driver from the passenger mutations (Lecault, Nature Me-
thods 2011). Fast or automatic techniques for genetic manipulation of cell lines have to 
be developed as current RNAi knockdown techniques and expression of mutated trans-
cripts are time consuming (Fujita, Methods Mol Biol 2010).
However, each model system has its own limitations, and it is possible that a specific 
genetic change in one cell type has no effect in another, or that an effect in vivo is not 
observed in vitro. As most commonly used glioma cell lines are high grade cell lines and 
have been cultured for many passages, genes that could be oncogenic in normal cells 
or low grade cell cultures, could not have an effect or (as we demonstrate in chapter 6) 
even an inverse effect on these high grade cell cultures. 
The best cell culture systems to test the effect of a gene on tumorigenesis is an oli-
godendroglial or astrocytic cell culture which only has a few oncogenic hits. Only then 
the effect on tumorigenesis can be established. The additional effect of an oncogene or 
the loss of a tumor suppressor gene on the proliferation rate of tumor cells could also 
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be usefully tested in cell lines of the tumor in which the alteration is discovered. This will 
mean that efficient systematic large scale projects have to be undertaken.  
Eventually, the effect of oncogenes and the loss of tumor suppressor genes has to be 
tested in the normal environment of tumor cells. We know that the surrounding stroma 
is also involved in tumorigenesis (Jones, Oncogene 2011) as well as in angiogenesis and 
in the immune reaction against tumor cells. Combined tumor and stroma cell cultures 
can be useful, but good animal models are necessary to make sure all microenvironmen-
tal factors are taken into account.   
Many infrequent “hills” could indicate that each tumor has its own unique spectrum of 
causal genetic changes. Treatments aimed at targeting these individual genetic changes 
may therefore be difficult. There are several ways to approach this problem. Firstly, it 
is likely that different genetic changes are part of a select set of molecular pathways 
(TCGA, Nature 2008). Therefore, pathway inhibition or reactivation can be used to target 
a broader range of tumors. Because of the fast evolutionary selection that is taking place 
in tumor growth (Navin, Nature 2011), a cocktail of targeted therapies will probably give 
the most promising results on tumor control. However, the problem of toxicity to normal 
cells has to be taken into account (for example see Reardon, Cancer Chemother Phar-
macol 2011). Good local administration of the drugs is an important factor in preventing 
unwanted toxicity, but a trade-off with the number of invasive tumor cells reached by 
the drugs is unavoidable. 
Apart from small molecule inhibition based on genetic changes, we can also use the 
tumor specific genetic alterations and the proteins they produce to target the tumor 
cells with specific antibodies or oncolytic viruses. For such targeting, however, only alte-
rations in proteins that are expressed on the cell surface can be used. A recent example 
of such a specific antibody is the EGFRVIII antibody CH12 (Jiang, J Biol Chem 2011). The 
big advantage of this tumor specific approach is the theoretically low toxicity to normal 
cells. 
In conclusion, large scale sequencing projects will unravel all genetic alterations in all 
different subtypes of glioma. The future challenge will be to translate these findings 
into clinical practice. For this we need to perform systematic functional analysis of these 
genetic alterations in appropriate cell cultures and animal models. In addition, we re-
quire the development of specific treatments that target these changes. Eventually, the 
knowledge of all these genetic alterations will be used to develop patient tailored tar-
geted therapy, in which all (tumor specific) genetic alterations of a patient will at first be 
helpful to predict the outcome to the in-use chemotherapeutics and in the future will 
decide which tumor specific drugs can be administered. As whole genome sequencing 
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will become more and more affordable in the near future, especially the first will soon 
become a realistic option.
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Summary
Gliomas are tumors with a dismal prognosis and it is therefore important to improve 
survival. The first step to accomplish this is to understand gliomagenesis at the mole-
cular level, and to discover all tumor suppressor and oncogenes. In chapter 1, the most 
important genetic alterations and their molecular pathways in gliomas are discussed. 
Affected pathways include EGFR/PI(3)K/AKT pathway, the P53 pathway and the RB pa-
thway in glioblastoma. In grade II and III gliomas LOH of 1p19q and the recently detected 
mutations in the IDH1 gene are very common. Chapter 2 gives a detailed overview of the 
IDH1 mutation frequencies, the IDH1 mutation types and the prognostic value of IDH1 
mutations in glioma patients. It also hypothesizes about the functional consequences of 
IDH1 mutations. 
In chapter 3 and 4, novel methods to detect genetic changes are described. In 
chapter 4 we identified transclocations using aberrant exon expression, in chapter 3 we 
identify translocations using integrated genomic approaches. Translocations identified 
include LEO1-SLC12A1 and EST AI364529-CASPR2. In chapter 3 RBBP4 was identified as 
a candidate oncogene and Pragmin as a candidate tumor suppressor gene. In chapter 4 
functional analysis of the CASPR2 gene showed that the translocation reduces CASPR2 
protein expression, 2 additional samples with loss of (part) of the CASPR2 gene were 
also identified and it was shown that glioma cells overexpressing CASPR2 had a reduced 
growth. CASPR2 therefore is likely to function as a tumor supressor gene in glioma.
In chapters 5 and 6 we focus on IDH1 mutations in glioma. In chapter 5 we find that 
IDH1 non-p.R132H mutations are unevenly distributed between histologic subgroups 
(less in classic oligodendrogliomas). They occur in gliomas harboring TP53 mutations, 
but are virtually absent in tumors with LOH of 1p19q.  Segregation in distinct subgroups 
could point to functional differences between IDH1 R132H and IDH1 non-p.R132H mu-
tations. In chapter 6 we functionally characterize IDH1 R132H mutations. Although IDH1 
R132H is a candidate oncogene, in glioma cell lines overexpression of IDH1 R132H resul-
ted in a reduced proliferation, both in vitro and in vivo. These cell lines also had a more 
cluster like and slower migration pattern. These results could give an explanation for the 
fact that IDH1 mutations are a positive prognostic marker. 
In chapter 7 we make use of Next Generation Sequencing to screen in oligodendro-
gliomas with LOH of 1p19q for genetic alterations (point mutations and small insertions 
and deletions) on these chromosomal arms. We enriched the DNA of 7 samples for all 
coding exons, miRNAs, splice sites and promoter regions on 1p and 19q using capture ar-
rays. We could not detect a common geneticly altered gene on 1p or 19q, thereby likely 
ruling out that the second hit on 1p or 19q is a genetic alteration in captured regions.
In summary, we describe several novel mechanisms to identify causal genetic chan-
ges in gliomas (chapter 3, 4 and 7), and characterize 2 of them (IDH1 and CASPR2).
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Samenvatting
Gliomen zijn tumoren met een erg slechte prognose en vaak fatale afloop. Het is daarom 
belangrijk om de vooruitzichten voor patienten te verbeteren. Een eerste stap in dit pro-
ces is de tumorgenese proberen te begrijpen op het moleculaire niveau en alle tumor-
suppressorgenen en oncogenen in kaart te brengen. 
In hoofdstuk 1 worden de belangrijkste genetische veranderingen in gliomen be-
sproken samen met hun moleculaire interacties in netwerken. Betrokken netwerken zijn 
het EGFR/PI(3)K/AKT netwerk, het P53  netwerk en het RB netwerk. In graad II en III gli-
omen komen het verlies van 1p19q en de recent ontdekte mutaties in het IDH1 gen vaak 
voor. Op het resterende 1p of 19q allel zou een tot nu toe onbekend tumorsuppressor-
gen kunnen zitten dat geheel uitgeschakeld wordt door een tweede genetische verande-
ring. Hoofdstuk 2 geeft een gedetailleerd overzicht van de IDH1 mutatiefrequenties en 
mutatietypen en de prognostische waarde van IDH1 mutaties in patiënten. Daarnaast 
komen er meerdere hypothesen aan bod over de functionele consequenties van IDH1 
mutaties. 
In hoofdstuk 3 en 4 worden nieuwe methoden om genetische veranderingen op te 
sporen beschreven. In hoofdstuk 4 identificeren we translocaties met behulp van exonen 
met een afwijkende expressie; in hoofdstuk 3 doen we dit met behulp van exon-expres-
siedata geïntegreerd met data over allelverlies. Translocaties die op deze manieren ge-
vonden zijn zijn LEO1-SLC12A1 en EST AI364529-CASPR2. Daar komt bij dat in hoofdstuk 
3 RBBP4 en Pragmin naar voren komen als kandidaat oncogen en tumorsuppressorgen. 
In hoofdstuk 4 laat de functionele analyse van het CASPR2 gen zien dat er geen expressie 
is van CASPR2 eiwit in de tumor met de translocatie, er 2 tumoren zijn waarin er verlies 
is van (een gedeelte van) het CASPR2 gen en dat overexpressie van CASPR2 in glioom 
cellen voor een verminderde groei van deze cellen zorgt. Het is daarom aannemelijk dat 
CASPR2 een tumorsuppressorgen is.  
Hoofdstuk 5 en 6 beschrijven de functionele analyse van mutaties in het IDH1 gen. In 
hoofdstuk 5 laten we zien dat IDH1 non-R132H mutaties onevenredig verdeeld zijn over 
histologische subgroepen (minder in klassieke oligodendrogliomen). Ze komen voor in 
gliomen met TP53 mutaties, maar zijn zo goed als afwezig in tumoren met verlies van 
1p19q. Deze seggregatie in specifieke subgroepen kan wijzen op functionele verschillen 
tussen IDH1 R132H and IDH1 non-p.R132H mutaties. In hoofdstuk 6 brengen we IDH1 
R132H mutaties functioneel in kaart. Hoewel IDH1 R132H een kandidaat oncogen is, la-
ten glioomcellen met overexpressie van IDH1 R132H een verminderde proliferatie zien, 
zowel in vitro als in vivo. Deze cellijnen hebben ook een langzamer en meer geclusterd 
migratiepatroon. Deze resultaten kunnen een verklaring geven voor het feit dat IDH1 
mutaties een positieve prognostische waarde hebben. 
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In hoofdstuk 7 maken we gebruik van Next Generation Sequencing technieken om in 
oligodendrogliomen met verlies van 1p19q te screenen voor genetische veranderingen 
(puntmutaties en kleine inserties en deleties) op 1p en 19q. Het DNA van 7 tumoren 
werd verrijkt voor alle coderende exonen, miRNA’s, splice sites en promoter regio’s op 
1p en 19q met behulp van capture arrays. We konden geen regelmatig aangedaan gen 
vinden op 1p of 19q. Hiermee sluiten we uit dat de uitschakeling van het tot nu toe 
onbekende tumorsuppressorgen op 1p/19q plaats vindt door middel van een tweede 
genetische verandering (ten minste voor de genen in de verrijkte regio’s). 
 
Samenvattend beschrijven we in dit proefschrift verscheidene nieuwe methoden om 
causale genetische veranderingen in gliomen te identificeren (hoofdstuk 3, 4 en 7) en 
analyseren we 2 van deze genen functioneel (IDH1 en CASPR2). 
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2009
2008
2007
0.4 ECTS
0.4 ECTS
0.4 ECTS
0.4 ECTS
0.4 ECTS
0.4 ECTS
0.4 ECTS
156
 
2. Teaching
Supervising MLO technicians in training
- Rosanna van der Dungen
- Lariesa Lapré
2008/2009
2009/2010
2 ECTS
2 ECTS
Organizing skills
- Board member Promeras (PhD representative organi-
zation)
- Member of the PhD committee
- EPAR faculty representative
2007/2010
2007/2010
2007/2008
2 ECTS
2 ECTS
2 ECTS
Uitnodiging
Voor het bijwonen van 
de openbare verdediging
van het proefschrift
Identification and 
Functional Analysis
of Genes Involved 
in Gliomagenesis
door 
Linda Bralten
Woensdag 14 december
13:30 uur
Arminiuskerk
Westersingel 76
Rotterdam
Na afloop bent u van 
harte uitgenodigd voor de 
aansluitende receptie  
en borrel in l’Ouest 
Van Oldenbarneveltstraat 139 
Rotterdam
Linda Bralten
Perponcherstraat 64
2518 SW Den Haag
l.bralten@erasmusmc.nl
Paranimfen
Anne Kleijn
annekleijn@gmail.com
Stephanie Kroeze  
stephanie_kroeze@hotmail.com
